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ABSTRACT 
In this thesis, a series of novel chromene derivatives based on three different moieties of 
biologically active compounds were synthesized and their antimicrobial and cytotoxic 
activities were evaluated in vitro. The fluorescent 8-amino-10-phenyl-5-hydroxy-2-oxo-4-
propyl-2H, 10H-pyrano [2,3-f] chromene-9-carbonitrile derivatives 2.2(a-j) were 
synthesized in good yields and with good fluorescence quantum yields (ΦF). The structures 
were confirmed on the basis of their spectral data and elemental analysis. The antimicrobial 
activity was investigated and tested against several human pathogens: Gram-positive, 
Gram-negative bacteria and fungi as well as mycobacterium using agar well diffusion 
method.  Minimum inhibitory concentrations were reported against each pathogen. All 
compounds showed significantly potent antimicrobial activities against most bacterial 
strains compared to reference drugs. Due to their structural similarity to reference drugs 
clorobiocin and novobiocin, docking experiments in the ATP binding pocket of DNA 
gyrase B enzyme revealed that the compounds mostly have the same binding mode as the 
reference drugs. Moreover, the cytotoxic activity was also evaluated against four different 
human cell lines and exhibited more potency than the reference drug. Several new 8-amino-
10-phenyl-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-diydro-2H,10H-pyrano[2,3-f] chro-
mene derivatives 3.2(a-g) were synthesized in good yield. The structures of these 
derivatives were established on the basis of IR, 1H NMR, 13C NMR, 1H-1H COSY, HSQC, 
HMBC and elemental analysis. All new synthesized compounds were evaluated for in vitro 
antimicrobial and cytotoxicity activities. Their antimicrobial activity was investigated and 
tested with seven human pathogenic Gram-positive and Gram-negative bacteria, four fungi 
and one mycobacterium, using agar well diffusion method, and minimum inhibitory 
concentrations were reported. Most of the new tested compounds exhibited significant 
potent antimicrobial activities against most bacterial strains compared to reference drugs. 
Some of these new synthesized derivatives exhibited the highest inhibitory activity against 
Pseudomonas aeruginosa (RCMB 010043), Escherichia coli (RCMB 010052) compared 
to reference drugs. On the other hand, three of these new compounds were found to be 
more effective against Salmonella typhimurium. The antibacterial activity of most 
compounds was found to be comparably active to reference drugs against Gram-positive 
bacteria, while compound 3.2c did not show any antimicrobial activity. The cytotoxic 
activity was also evaluated against four different human carcinoma cell lines and exhibited 
good cell growth inhibitory activity against HCT-116 cell line. The molecular modeling 
results showed binding interaction of some new synthesized compounds in the active site 
of Gyrase B. A variety of novel derivatives of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-
4H-benzo[h]chromene-3-carbonitrile 4.2(a-j) have been prepared via three component 
reactions. The structures were confirmed on the basis of their spectral data and elemental 
analysis. Their antimicrobial activity was investigated and tested against four human 
pathogen Gram-positive and Gram-negative bacteria and four fungi. Some newly prepared 
compounds exhibited antimicrobial activities against Gram-negative bacteria and fungi 
species compared to reference drugs. The bathochromic shift of compound 4.2a was shown 
in solution when acidified. Moreover, the cytotoxic activity was also evaluated against 
three different human cell lines. Some tested compounds have good IC50 against HCT-116 
and MCF-7 cell lines. The molecular modeling results showed binding interaction of some 
new synthesized compounds in the active site of Gyrase B. 
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Chapter One: Introduction  
1.1 Scope of present work 
This thesis focuses on the synthesis of new bioactive amino chromene compounds based 
on three selected heterocyclic groups. Chapter Two focuses on the study of the anti-
microbial activity of coumarins. Derivatives of 5,7 dihydroxy alkyl coumarin 2.1 were used 
for the generation of novel derivatives of chromene based coumarins and in vitro testing of 
their antimicrobial and cytotoxic effects, and the fluorescence properties of these 
compounds is discussed. Chapter Three focuses on the preparation of several novel 
chromene derivatives based on flavanone moiety and the study their antimicrobial and 
antitumor properties with docking studies. The work in Chapter Four encompasses 
synthesis of new chromene derivatives by combination with azo dye and their antimicrobial 
and antitumor activities and the docking studies are discussed in detail. The purpose of 
developing these chromene derivatives is to create novel antimicrobial agents that are 
biologically active especially against infectious diseases, which are one of the most 
responsible factors for a significant proportion of deaths. 
 
1.2 Chromenes 
Heterocyclic chemistry is one of the most complex branches of organic chemistry and 
heterocyclic compounds are considered the largest family of organic compounds. In fact, 
these compounds are characterized by their ability to provide structural diversity and have 
proven to be useful as therapeutic factors.1 Heterocyclic molecules incorporating oxygen  
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atoms are of special interest and the most important heterocyclic rings containing oxygen 
are generally tetrahydropyran (6-member). One of the most interesting classes of these 
materials is the class of chromene compounds.  The structure of these molecules includes 
benzene and pyran rings which are fused together with various levels of saturation. The 
structures of 1-benzopyrans include various structures such as chromane 1.1, 2H-chromene 
1.2 and 4H-chromene 1.3 and chromone 1.4 as shown in Figure 1.1. 
O O OO
O
1.1 1.2 1.3 1.4  
Figure 1.1: Different structures of 1-benzopyrans compounds.2, 3 
 
Chromenes are a group of biologically active molecules occurring extensively in nature 
with a wide range of molecular modifications.4 They exhibit a variety of biological effects 
including anti-microbial5, anti-viral6,7, anti-inflammatory8, anti-oxidants9, anti-
proliferative10, anti-tumor11, anti-Alzheimer’s and anti-Parkinson disease12-14, estrogenic15, 
antifungal16, anti-HIV17 and CNS activity.18 In addition to their biological activity, certain 
chromene molecules have been used to produce highly effective fluorescent dyes for 
synthetic fibers, daylight fluorescent pigments, electro photographic and 
electroluminescent devices.19,20 
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1.2.1 Naturally occurring chromenes  
For thousands of years a number of 4H-chromene moieties are found in a large number of 
naturally occurring compounds such as leaves and stems of plants and sometimes from the 
roots. Examples of naturally occurring 4H-chromene are 7-hydroxy-6-methoxy-4H-
chromene 1.5 and 6,7-dimethoxy-4H-chromene 1.6 which were isolated from the flower 
of Wisteria sinensis that exhibit organoleptic activities (Figure 1.2).  
O
HO
MeO O
MeO
MeO
1.5 1.6  
Figure 1.2: Structure of 7-hydroxy-6-methoxy-4H-chromene and 6,7-dimethoxy-4H- 
chromene.2 
 
1.2.2 Pharmacological potent and drug like synthetic chromene 
A series of synthetic chromene derivatives have significant pharmaceutical potential. Some 
of them are currently in use as potent drugs and others are in clinical trials. For examples, 
diethyl 2-(2-amino-6-bromo-3-cyano-4H-chromen-4-yl) malonate 1.7 and 9-amino-7-(3-
bromo-4,5-dimethoxyphenyl)-3- methyl - 7H - pyrano [2,3-f] quinoxaline-8-carbonitrile 
1.8 which are now being developed as anticancer agents. The 2-amino-5, 10b-dihydro-5-
oxo-4-phenylpyrano[3,4-c] chromene-1-carbonitrile 1.9 is used as an antibacterial agent.  
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In addition, 2-amino-4-(3-nitrophenyl)-4H-benzo[h]chromene-3-carbonitrile 1.10 exhibits 
anti-rheumatic effect (Figure 1.3).  
O
CN
NH2
Br
O
OO
O
O N
N
H2N
NC
Br
OMe
OMe
1.7 1.8
O
O
O
NH2
NC
O
NH2
CN
NO21.9 1.10  
Figure 1.3: Some of the synthetically important drug-like chromene heterocycles.21-25 
 
Due to extensive pharmacological applications, chromene heterocycles have considerable 
interest during the last several years among chemists to develop a useful method to 
synthesize diverse chromenes with potential interest.  
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Intense research has been focused on amino-4H-chromene and its derivatives have been 
recognized as one type of privileged medicinal scaffolds due to their unique 
pharmacological and biological activities. Many structures that contain an amino-4H-
chromene moiety exhibit excellent biological effects.26   
 
1.2.3 General methods for the synthesis of 4H-chromenes  
In recent years, the multi-component reaction (MCR) has been used to synthesize 4H-
chromene and its derivatives. In general, 4H-chromenes are prepared by condensation of 
activated phenol, various aldehydes and malononitrile 1.11 in the presence of organic 
bases. The reaction goes through Knoevenagel condensation product from aromatic 
aldehydes and malononitrile 1.11. Finally, the reaction followed by Michael addition 
involving active methylene compound 1.12 and Knoevenagel product 1.13 to afford 4H-
chromene 1.14 as shown in the (Scheme1.1). 
CN
H
CN
R`
Base
O
CN
NH2
R`
OH
OH
R
OH
R
1.12 1.13 1.14  
Scheme 1.1: General protocol for synthesis of amino-4H-chromene molecules.27  
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Recently, numerous reports are cited in literature in which the various catalysts have been 
employed for synthesis of amino-4H-chromene derivatives.  
 
In 1962, novel 2-aminopyrano [3, 2-c] benzopyran derivatives were prepared by reaction 
of 4-hydroxycoumarin 1.15 with malononitrile 1.11 and aromatic aldehyde 1.16 in pyridine 
as a solvent to give desired derivative 1.17 (Scheme 1.2).  
O OH
Ar
O OO
OH
1.15 1.16 1.17
CN
CN
1.11
O
NH2
CN
ArPyridine
Ar = C6H5
Scheme 1.2: Synthesis of 2-amino-3-cyano-4H-chromenes by Wiener and co-workers.28  
 
Ballini et al. reported the synthesis of 4-aryl-4H-chromene heterocycles (1.18, 1.19, 1.20) 
via three-component reaction in 2001.  The synthetic pathway included condensation 
between substituted aryl aldehyde 1.16, malononitrile 1.11 and substituted phenols (21, 22, 
23) in the presence of cetyltrimethylammonium chloride (CTACl) as catalyst in water 
under reflux (Scheme 1.3).  
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OH
Ar
1.16
CN
CN
1.11
Ar = -NO2C6H4, -ClC6H4, Pyridyl, -OCH3
R = OCH2O
-, -OCH3
H2O, 110oC
Time: 6-8h
OH
OH
OH
R
O
CN
NH2
Ar
O NH2
CN
Ar
R
O NH2
CN
Ar
1.18
1.19
1.20
1.21
1.22
1.23
CTACl
Scheme 1.3: CTACl catalyzed one-pot synthesis of 4-aryl-4H-chromenes.29  
 
In 2002, Shestopalov et. al. reported the synthesis of substituted 2-amino-4H-chromenes 
1.24 by three component reaction of naphthalenediol 1.25, aromatic aldehyde 1.16 and 
malononitrile 1.11 in the presence of trimethylamine as a catalyst in ethanolic solution 
(Scheme 1.4).  
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OH
Ar
OH
1.25 1.16 1.24
CN
CN
1.11
Ar = 4-ClC6H4, -C6H5
OH
(CH3)3N O
O
CN
Ar
NH2
Ar
NC
NH2
 
Scheme 1.4: Synthesis of substitutes 2-amino-4H-chromenes in triethyl amine.30  
 
Novel 2-amino-4H-benzo[h]chromenes 1.18, 1.20 were synthesized by multi-component 
reaction in 2004. The synthetic pathway included condensation between malononitrile 
1.11, aromatic aldehyde 1.16 and 1- and 2-naphthols (1.23, 1.21) and using cetyltrimethyl 
ammonium bromide (CTABr) as a catalyst in water medium under ultrasonic irradiation 
(Scheme 1.5). 
OH
Ar
1.16
CN
CN
1.11
Ar = -NO2C6H4, -ClC6H4, -OHC6H4, -OCH3
CTABr, H2O
us, rt
OH
OH
O
CN
NH2
Ar
O NH2
CN
Ar
1.18
1.20
1.21
1.23
Scheme 1.5: Synthesis of 2-amino-4H-benzo[e]chromenes using CTABr under US.31  
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In 2005, two novel 2-amino-3-cyano-4H-benzo[h]chromenes (1.26, 1.27) were prepared 
by reacting malononitrile 1.11 with aryl aldehydes 1.16 and 2-naphthol 1.21 or resorcinol 
1.28 under microwave irradiation (MW) in K2CO3 as a catalyst (Scheme 1.6). Most of 
synthesized derivatives have in vitro antibacterial activity.32 
OH
R
1.16
CN
CN
1.11
R= -Piperonyl, Indolyl, 2-Chloro-3-quinolyl
aq. K2CO3
OH
O
CN
NH2
R
O NH2
CN
R
1.26
1.27
1.21
1.28
OH
HO
MW
OH
Scheme 1.6: Synthesis of 2-amino-4H-chromenes under (MW) in aqueous medium.  
 
In 2007, new 2-amino-4H-chromene derivatives were synthesized by the reaction of 
malononitrile 1.11 or ethyl cyanoacetate 1.29 with salicylaldehyde 1.30 in the presence of 
a catalytic amount of amberlyst A-21 in ethanol as a solvent at room temperature to afford 
the 1.31 and 1.32 compounds in high yield (Scheme 1.7).  
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1.30
Amberlyst-21
1.11
1.29
EtOH, r.t
CNNC
NC
O
O
O
CN
NH2
1.31
NC CN
O
CO2Et
NH2
1.32
NC CO2Et
OH
H
O
Scheme 1.7: Synthesis of 2-amino-4H-chromenes using Amberlyst A-21in ethanol.33   
 
In 2008, novel of 2-amino-4H-chromene derivatives were prepared via combination of 
malononitrile 1.11, aromatic aldehyde 1.16 and 1- and 2-naphthol (1.23, 1.21) in the 
presence of methanesulfonic acid as a catalyst in acetonitrile to given excellent yield of 
1.18 and 1.20 compounds (Scheme 1.8).  
11 
 
OH
Ar
1.16
CN
CN
1.11
Ar = 3-NO2C6H4, 4-ClC6H4, 4-CH3OC6H4
OH
OH
O
CN
NH2
Ar
O NH2
CN
Ar
1.18
1.20
1.21
1.23
Methanesulfonic acid
CH3CN, reflux
Scheme 1.8: Synthesis of 2-amino-4H-benzo[e]chromenes in methane sulfonic acid.34  
In 2008, novel of 2-amino-4H-chromene derivatives were synthesized in good yield by 
simple electrocatalytic system. The synthetic pathway included condensation between 
resorcinol 1.28, malononitrile 1.11 and aromatic aldehyde 1.16 in the presence of dry 
propanol and current density of 10 mA/cm2 (I=50 Ma, electrode surface= 5cm2) to give 
1.33 compounds (Scheme 1.9). 
OH
R
1.16
CN
CN
1.11
Ar= 4-ClC6H4, 4-MeOC6H4, 4-FC6H4, 4-BrC6H4, 2,4-FC6H4
propanol
O NH2
CN
Ar
1.331.28
OH
HO
NaBr, 50mA
OH
 
Scheme 1.9: Synthesis of 2-amino-4H-chromenes by electrocatalytic system.35  
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In 2010, the 2-amino-4H-chromene derivatives 1.33 were prepared by using microwave 
(MW) by condensation between resorcinol 1.28, malononitrile 1.11 and suitable aromatic 
aldehyde 1.16 in ethanolic solution. The authors used 1,8-diazabicyclo (5.4.0) undec-7-ene 
(DBU) as catalyst for this reaction (Scheme 1.10).  
OH
Ar
16
CN
CN
11
Ar= 4-ClC6H4, 4-MeOC6H4, 4-FC6H4, 
4-BrC6H4, 2,4-F2C6H4, 3-NO2C6H4
MW, DBU
O NH2
CN
Ar3328
OH
HO
EtOH, 50oC
OH
Scheme 1.10: Synthesis of 2-amino-4H-chromenes by using DBU under MW.36  
 
Khurana et al. reported the synthesis of 2-amino-4H-benzo[h]chromene derivatives 1.34 
in 2010. The synthetic pathway included condensation between malononitrile 1.11, 
aromatic aldehydes 1.16, and 1-naphthol 1.23 in the presence of 1, 8-diazabicyclo (5.4.0) 
undec-7-ene (DBU) as a catalyst. This method was useful due to the short reaction time 
and mild conditions (Scheme1.11). 
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OH
Ar
1.23 1.16 1.34
CN
CN
1.11
Ar = 4-BrC6H4, -4-CH3C6H4, 3,4,5-(CH3)3C6H2, 3,4-(CH3)2C6H3
DBU
O
CN
Ar
NH2
H2O
reflux
OH
 
Scheme 1.11: Synthesis of substitutes 2-amino-4H-chromenes by DBU in water.37 
 
In 2011, 2-amino-5-hydroxy-4H-chromene 1.35 was prepared by one pot synthesis of 1-( 
2, 4-dihydroxyphenyl) ethanone 1.36 and 2-benzylidene malononitrile 1.37 in the presence 
of calcium hydroxide in methanol at room temperature (Scheme 1.12). 
1.36 1.37 1.35
O
CN
NH2
OHO
OH
CN
CN
Ca(OH)2
Methanol
O OH
 
Scheme 1.12: Synthesis of 2-amino-4H-chromene in the presence of calcium hydroxide.38 
 
In 2011, 2-Amino-4-(4-halophenyl)-7-(diethylamino)-4H-chromene-3-carbonitrile 1.38 
compounds were prepared by reaction between 3- N, N-diethylaminophenol 1.39 and  
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ethyl α-cyanocinnamonitriles 1.40 in ethanol and used piperidine as catalyst (Scheme 
1.13). Some of these derivatives have cytotoxic effect and antimicrobial activity.39  
1.39 1.40
1.38
O
CN
NH2
OH
CN
CN Ethanol
N X
Piperidine
X= F, Cl,Br
Scheme 1.13: Synthesis of 2-amino-4H-chromene in the presence of piperidine. 
 
Babu et al reported the synthesis of azido 2-amino-4H-chromene 1.41 in 2011. The 
synthetic pathway included condensation between 3-bromesalicylaldehyde 1.42, 
malononitrile 1.11 and phenyl azide 1.43 in ethanolic piperidine solution at room 
temperature (Scheme 1.14).  
Ethanol, rt, 55min
40 mol% piperidine
1.431.42 1.41
CN
CN
1.11
Br
O
CN
NH2
OH
N3
N3
O
CHO
O
Scheme 1.14: Synthesis of azido 2-amino-4H-chromene in the presence of piperidine.40  
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In 2011, another one-pot synthetic route has been carried out by reaction of 4-
hydroxycoumarin 1.15, aromatic aldehyde 1.16 and malononitrile 1.11 in water to afford 
the 3,4-dihydropyrano chromenes 1.17 in high yield using CuO nanoparticles as a catalyst 
(scheme 1.15)  
O
OH
Ar
O OO
OH
1.15 1.16 1.17
CN
CN
1.11
O
NH2
CN
Ar
Ar = C6H5, 4-NO2C6H4, 3-ClC6H4, 2-CH3C6H4, 4-CH3OC6H4
CuO nanoparticles
H2O, Reflux
 
Scheme 1.15: Synthesis of 2-amino-3-cyano-4H-chromenes using CuO nanoparticales.41 
 
In 2011, Sheibani et al. reported the synthesis of 2-amino-3-cyano-4-aryl-4H-benzo[h]-
chromenes 1.44 by condensation between malononitrile 1.11, 4-chloro1-naphthol 1.45 and 
substituted aromatic aldehydes 1.16 under reflux and catalyzed by MgO in DMF (Scheme 
1.16). Some of these synthesized compounds were evaluated for their anxiolytic 
activities.42  
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OH
Ar
1.45 1.16 1.44
CN
CN
1.11
Ar = 4-BrC6H4, , 4-ClC6H4, 4-FC6H4
MgO
DMF
reflux
OH
Cl
O
Ar
NH2
CN
Cl
 
Scheme 1.16: One-pot synthesis of substitutes 2-amino-3-cyano-4-aryl-4H-benzo[h] 
chromenes in MgO. 
 
In 2012, 2-amino-3-cyano-4- arylsulfanyl-4H-chromenes (1.46, 1.47, 1.48) were 
synthesized by condensation between malononitrile 1.11, substituted salicylaldehydes (2-
hydroxynaphthalene-1-carbaldehyde 1.49 or 5-bromo-2-hydroxybenzaldehyde 1.42 or 2-
hydroxybenzaldehyde 30) and thiols 1.50 in the presence of [Bmim]BF4 at room 
temperature (scheme 1.17). 
17 
 
1.50
CN
CN
1.11
R = H, CH3 , OCH3
[Bmim]BF4
30min
CHO
CHO
CHO
1.46
1.30
1.42
1.49
SH
R
OH
OH
Br
OH
O
S
CN
NH2
R
O
S
CN
NH2
R
Br
O
S
CN
NH2
R1.47
1.48
Scheme 1.17: Ionic liquid-catalyzed multicomponent synthesis of 2-amino-3-cyano-4-
arylsulfanyl-4H-chromenes.43 
 
In 2013, novel 2-amino-7-hydroxy-4H-chromenes 1.51 were prepared by multi component 
reaction between resorcinol 1.28, malononitrile 1.11, and substituted aryl aldehyde 1.16 
without a catalyst in water medium using ultrasound irradiation (Scheme 1.18).  
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This methodology displayed several advantages over other procedures. It is green, under 
mild conditions, fast reaction time, and higher yield and selectivity without need for a 
transition metal or base catalyst.44 
H2O
60 oC, u.s.
OH
Ar
1.16
CN
CN
1.11
Ar= 3-ClC6H4, 2-FC6H4, 4-BrC6H4, 
2,4-Cl2C6H4, 4-MeC6H4, 2-naphthyl
O NH2
CN
Ar
1.51
1.28
OH
HO
OH
Scheme 1.18: Synthesis of 2-amino-7-hydroxy-4H-chromenes under ultrasonic in water. 
 
Sinha et al. prepared 2-amino-3-cyano-4-phenyl-4H-benzo[h]chromene 1.52 in 2013, by 
condensation between malononitrile 1.11, benzaldehyde 1.16 and 1-naphthol 1.23 in water 
to produce the desired products (Scheme 1.19). 
H2O, reflux
1.16
CN
CN
1.111.23
OH
KI/ K2CO3/ I2
CHO
O
CN
NH2
1.52  
Scheme 1.19: Synthesis of 2-amino-4-phenyl-4H-benzo[h] chromene-3-carbonitrile.45 
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Several of novel 4H-benzo[h]chromene derivatives 1.20 were synthesized in 2013, by 
condensation between malononitrile 1.11, substituted aryl aldehydes 1.16 and 1-naphthol 
1.23 in water medium under reflux and catalyzing by hydroxyapatite (HA) or sodium 
modified hydroxyapatite to afford good yields of products (Scheme 1.20). 
H2O, reflux
1.16
CN
CN
1.111.23
OH CHO
O
CN
NH2
1.20
R
R = -Cl, -NO2, -CH3, -OCH3
R
HA
Scheme 1.20: Hydroxyapatite-catalyzed one-pot synthesis of 4H-benzo[h]chromenes.46 
 
In 2013, several new 2-amino-3-cyano-4H-chromene derivatives 1.18 were prepared   by 
condensation of aromatic aldehyde 1.16, malononitrile 1.11 and 2-aphhol 1.21 in the 
presence of poly (4-vinylpyridine) catalyst (Scheme 1.21). The main features of the present 
catalyst are that it is green, commercially available and efficiently recyclable.47 
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1.16
CN
CN
1.111.21
CHO
R
R = -Cl, -Br, -NO2, -CH3, -OCH3
PVPy
Solvent-free, 80 oC
OH
O
NH2
CN
R
1.18
 
Scheme 1.21: Synthesis of 4H-benzo[h]chromenes catalyzed by Poly(4-vinylpyridine). 
 
Kiyani et al. synthesized 2-amino-4-aryl-7-hydroxy-4H-chromene-3-carbonitrailes 1.33 
and 2-amino-5-oxo-4-aryl-5,6,7,8-tetrahydro-4H-chromenes 1.53, 1.54 by Knoevenagel 
condensation between suitable aromatic aldehydes 1.16, malononitrile 1.11 or ethyl 
cyanoacetate 1.29 with resorcinol 1.28 to afford 1.33 and with cyclohexane-1,3-dione 55 
or 5,5-dimethylcyclohexane-1,3-dione 1.56 to give compounds 1.53, 1.54. In this reaction 
potassium phthalimide was used as the organocatalyst (Scheme 1.22). The main 
advantages of the present procedure are that it is green, the short reaction times, high yields 
and avoiding the use of hazardous organic solvents.48  
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1.16
CN
X
R = CL, OH,NO2 ,
 (CH3)2N, CH3 ,-OCH3
PPI, H2O
reflux
1.33
1.28
1.55
1.56
CHO
OH
1.53
1.54
R
1.11 X=CN   
1.29 X=COOEt
OH
O
CN
NH2
R
HO
O
O
O
O
O
X
NH2
O
R
O
X
NH2
O
R
Scheme 1.22: Synthesis of 2-amino-4-aryl-4H-chromenes catalyzed by PPI 
In 2015, several new of indol-3-yl-4H-chromenes were prepared via multi-component 
reaction between salicylaldehyde 1.30, malononitrile 1.11 or ethyl cyanoacetate 1.29 and 
indoles (1.57, 1.58, 1.59, 1.60) in the presence of tetra-butyl ammonium glycinate 
[TBA][Gly] as a catalyst under solvent free conditions at 60 oC (Scheme 1.23) to afford  
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new 2-amino-4H-chromene derivatives (1.61, 1.62, 1.63,1.64). This method is metal free 
and produced high yield The molecular modeling results showed binding interaction of 
some new synthesized compounds in the active site of Gyrase B in short reaction times.49 
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Scheme 1.23: One-pot synthesis of indol-3-yl-4H-chromenes catalyzed by [TBA][Gly]. 
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In the same year, Mansoor et al. prepared 3,4-dihydropyrano[3,2-c] chromene derivatives 
1.17, 1.65 by reaction of substituted aryl aldehydes 1.16, ethyl cyanoacetate 1.29 or 
malononitrile 1.11 and 4-hydroxycoumarin 1.15 in the presence of thiourea dioxide (TUD) 
in aqueous medium at 70 oC (Scheme 1.24). This technique has several advantages 
including mild reaction conditions, affording the products in excellent yields and easy 
purification. In addition, thiourea dioxide is low cost and non-volatilc.50  
1.16
1.11
1.29
water
CNNC
NC
O
O
1.17
1.65
CHO
R TUD
O O
OH
1.15
O O
O
CN
NH2
R
O O
O
COOC2H5
NH2
R
R =F, Cl, Br, NO2, CH3, OH
 
Scheme 1.24: Synthesis of 2-amino-4H-chromenes using thiourea dioxide (TUD). 
 
In 2016, novel derivatives of 2-amino-4H-benzo[h]chromene were synthesized by reacting 
aromatic benzaldehydes 1.16, malononitrile 1.11 or ethyl cyanoacetate 1.29 and 4-
methoxy-1-naphthol 1.66 in the presence of piperidine in ethanolic solution under (MW)  
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to afford 1.67 and 1.68 (Scheme 1.25). Most of synthesized compounds have cytotoxic 
activity against three cancer cell lines (MCF-7, HCT-116 and HepG2).51 
1.16
1.11
1.29
MW, EtOH
CNNC
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1.67
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Br
 
Scheme 1.25: Synthesis of 2-amino-4H-benzo[h]chromenes under (MW) in piperidine. 
 
Elinson et al. prepared new 2-amino-4-substituted-4H-chromene derivatives in 2016 by 
pseudo four-component reaction of salicylaldehyde 1.30, cyclic ketones 1.69 and two 
molecules of malononitrile 1.11 in the presence of sodium acetate at ambient temperature 
to afford compounds 1.31 and 1.70 (Scheme 1.26). 
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Scheme 1.26: Synthesis of new 2-amino-3-cyano-4H-chromenes in the sodium acetate.52 
 
1.3 Coumarins 
Coumarin (2H-1-benzopyran-2-one) 1.73 is classified as a member of the benzopyrone 
family. It consists of a benzene ring joined to a pyrone ring (Figure 1.4). Coumarins are 
found in plant products such as vegetables, fruits, seeds, nuts, coffee, tea, and chicory. The 
first extraction of this naturally occurring compound was published in 1820.53 Furthermore, 
coumarins are found in various essential oils such as cinnamon bark oil, cassia leaf oil, and 
lavender oil.  
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This compound was synthesized and the first synthesis of coumarin was published in 
1868.54, 55  
O O
1.73  
Figure 1.4: The chemical structures of coumarin 
 
Coumarins are classified into four main subtypes, including simple coumarins, 
furanocoumarins, pyrancoumarins, and the pyrone-substituted coumarins.54, 55 Simple 
coumarins based on the derivatives of the coumarin along with their glycosides, including 
alkoxylated, hydroxylated, and alkylated. Coumarin, 7-hydroxycoumarin 1.74 and 6,7-
dihydroxycoumarin 1.75 are examples of this subtype. Coumarins that consist of a five-
membered furan ring attached to the coumarin structure known as furanocoumarins such 
as angelicin 1.76. This subtype divided into linear or angular type based on the benzoid 
position.54-56 Seselin 1.77 belongs to the pyranocoumarins, which consist of a six 
membered ring attached to a benzene ring. 4-hydroxycumarin 1.15 attached with pyrone 
ring that substituted with coumarins are the basic structure to form last coumarin subtype, 
pyrone substituted coumarins such as warfarin 1.78 as shown in (Figure 1.5). 
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Figure 1.5: The chemical structures of examples of the four main coumarin subtypes.54-56  
 
In recent years, coumarins have been classified into six minor types, which have been 
isolated from the fruits and the stem bark of Calophyllum dispar (Clusiaceae).54 Few 
coumarins have been extracted from microbial sources. Aflatoxin B1 1.79 is the most 
commonly occurring member of the aflatoxins group, which possess antifungal activity 
and are extracted from Aspergillus. Furthermore, coumermycin A1 1.80, novobiocin 1.81 
and clorobiocin 1.82 have been isolated from Streptomyces (Figure 1.6). These plant 
coumarins exhibited antibiotic properties, which are potent inhibitor of DNA gyrase.54, 55  
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Figure 1.6: Some important coumarin members isolated from microbial sources. 
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These natural products have exhibited various biological significance, including anti-
inflammatory,57,58 antifungal,59 antiviral,60 anticancer,61,62 and anti-HIV63 properties. 
Furthermore, coumarins have been used as a chemopreventitive agent, mainly against 
breast cancer in animal models.64, 65, 66  
 
1.4 Flavanone 
Some natural compounds are very similar in structure and biological activity. These 
naturally occurring compounds were used for medicinal purposes. Flavonoids are one of 
these compounds, which are found in plants foods such as fruit, vegetables, tea, and 
legumes.67 First experiment described the biological activity of flavonoid was discovered 
in 1936 by Rusznyak and A. Szent-Gyorgyi. This flavonoid was then named vitamin P 
1.83, which were extracted from Hungarian red pepper (Figure 1.7).  
O
O
OH
OOH
O
OH
OH
HO
O
O
HO
HO
OH
1.83  
Figure 1.7: Chemical structure of vitamin P 
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Five decades later, researcher studied the benefits of flavonoids in the treatment of a 
various diseases, including pregnancy toxaemia, rheumatic fever, diabetes and cancer. 
From 1980 to 1990, researchers discovered that flavonoids have variety in biological 
actions as mutagenic agents, antioxidants and pro-oxidants. A year later, the antioxidant 
activity of this group was discovered in vitro. However, few years later the studies showed 
that the antioxidant activity of flavonoids in vivo could not account for the overall actions 
attributed to them.68 Flavonoids have widespread classification, over more than 10,000 
structures, and are subdivided into flavone 1.84, flavanone 1.85, flavanonol 1.86, flavan 
1.87 and anthocyanidin 1.88 (Figure 1.8). Flavanones are considered as a class of 
flavonoid group, which occur naturally in many fruits and vegetables especially those with 
dark colors. Flavanones are glycosylated by a disaccharide at position seven to give 
flavanone glycosides.68-71  
1.84
O
O
1.85
O
O
1.86
O
O
OH
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1.87
O
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Figure 1.8: Some chemical structures of flavonoid subtypes.  
 
The main aglycones of flavanones are naringenin 1.89 and hesperetin 1.90 (Figure 1.9), 
but they are more commonly found in glycosides71. Most of these compounds have 
biological significance such as anti-inflammatory, antimicrobial, cytotoxic, and 
antioxidant.69-71 However; few studies have been published and described the biological 
activities of flavanones. Therefore, the purpose of this research was to synthesize a new 
bioactive compound based on flavanone.  
OHO
OH O
OH
OHO
OH O
O
OH
1.89 1.90  
Figure 1.9: Chemical structures of the main aglycones of flavanones.  
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1.5 Azo chromophores 
Over the years, azo dyes have been considered as an important class of organic colorant, 
which are based into two classes, named pigments and dyes. The key distinction is that 
pigments are insoluble in the medium while dyes are soluble in the medium to which they 
are added. Both types have widespread of commercial classifications, and have been used 
for manufacturing purposes. Azo dyes are compounds that contain at least one conjugated 
azo group (-N=N-) joined to a methine, aromatic, heterocyclic system by sp2-
hybridization.72,73 Azo groups are relatively strong and chemically stable.74 Azo compound 
structures are composed of two main parts. The first part contains at least one or more 
auxochrome moieties such as -NH2, -OH, -COOH, -SO3H, while the second part is 
aromatic groups which are called chromophores. The Auxochrome moieties are 
responsible for increasing the color intensity and the affinity with the fibers. The dye 
molecule is often described as a chromogen.75,76 Azo chromophores exist in two stable 
isomeric states; the trans (E) and the cis (Z) forms.77,78 The azo chromophore can switch 
between these isomers upon absorption of a photon. Azo dyes were extracted from natural 
sources based on animals and vegetables by the mid nineteenth century. However, the 
natural colorants were replaced with manufactured dyes by the beginning of twentieth 
century. The historical usage of synthetic dyes started in 1856. William Henry Perkin 
discovered the first commercially synthetic azo dye, named mauveine or aniline purple 
1.91, and orange dye 1.92 was discovered in 1876. (Figure 1.10). 79-81 
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Figure 1.10: Chemical structures of some azo compounds isolated from natural sources 
 
Years later, azo dyes have been used for dyeing purposes such as fabric, paper, leather, 
plastic, cosmetics, among others.81-83 Furthermore, azo colorants show a variety of 
biological activity such as antibacterial, antifungal, and anti-HIV activities.80-85 One of the 
famous instances of azo dyes is their use in therapeutic treatments of prontosil rubrum 1.93, 
which has been widely used in the treatment of serious bacterial illness (Figure 1.11). 
1.93
N
NH2
H2N
N
SO2NH2
 
Figure 1.11: Chemical structures of prontosil rubrum.  
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 1.6. Aims of the research 
In this thesis, the overall objective is to synthesis and characterize a series of novel 
chromene derivatives based on three different moieties of biologically active compounds 
including coumarin, flavanone and azo dyes. After that I will study in vitro antimicrobial 
and anti-cancer for these derivatives. The docking experiments in the active site of DNA 
gyrase B enzyme of these compounds will be studied. The objective of this study to 
understand the biologically active of chromenes when combine with other biological active 
moiety to develop the drugs of bacterial and cancer. 
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Chapter Two: Synthesis and Characterization of chromene based coumarin 
derivatives 
 
2.1 Synopsis 
A series of novel fluorescent 8-amino-10-phenyl-5-hydroxy-2-oxo-4-propyl-2H,10H-
pyrano[2,3-f] chromene-9-carbonitrile derivatives 2.2(a-j) were synthesized in good yield 
and with good quantum yields (ΦF). The structures were confirmed on the basis of their 
spectral data and elemental analysis. Their antimicrobial activity was investigated and 
tested against seven human pathogen Gram-positive and Gram-negative bacteria: Bacillus 
cereus, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, four fungi: 
Aspergillus niger, Aspergillus flavus, Fusarium oxisporum, Rhizopus stolonifer and one 
mycobacterium, Mycobacterium tuberculosis, using the agar well diffusion method and 
minimum inhibitory concentrations were reported. The fluorescence properties of these 
compounds afford unique opportunities to examine their intracellular localization. All of 
the designed compounds showed significant potent antimicrobial activities against most 
bacterial strains compared to reference drugs. The most active novel compounds 2.2f and 
2.2g (IZ, around 25 mm and MIC, 0.49-3.9 µg/mL) were subjected to different molecular 
modeling protocols for study of their activity mechanisms, due to their structural similarity 
to reference drugs clorobiocin and novobiocin. The docking experiments in the ATP 
binding pocket of DNA gyrase B enzyme revealed that the compounds mostly have the 
same binding mode as the reference drugs.  
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Moreover, the cytotoxic activity was also evaluated against four different human cell lines 
and exhibited more potency than the reference drug.  
 
2.2 Introduction  
Infectious diseases are one of the most responsible factors for a significant proportion of 
deaths worldwide and, according to the WHO, antimicrobial agents are considered to be 
“miracle drugs” that are used in the treatment of such diseases.86 Unfortunately, clinically 
efficacious antimicrobial agents are becoming less effective due to the resistance caused 
and gradual appearance of drug-resistant strains among infected communities.87 Therefore, 
there is an urgent need for the discovery or optimization of novel antimicrobial agents that 
are active especially against these resistant strains.88 Coumarins and dihydropyran 
derivatives are the most important heterocyclic compounds with diverse and interesting 
biological activities. Coumarins are a group of biologically active molecules occurring 
extensively in nature with a wide range of molecular modifications.89 They exhibit a variety 
of biological effects including antiviral,57 anticancer,58,59 anti-fungal,60 anti-
inflammatory61,62 and anti-HIV63 properties. They especially show potent antibacterial 
effects against Gram-positive species.90  Plant coumarin antibiotics such as novobiocin and 
clorobiocin have potential antimicrobial activity by affecting the functioning of DNA 
gyrase, which is the basis for their broad spectrum antibacterial activity.91,92 The nature and 
positions of substituents define coumarin activity, and coumarin substitution in positions 3 
and 7 is necessary for antimicrobial activity.93  
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Some natural coumarin-based derivatives have been found to possess anti-microbial effects 
on methicillin-resistant Staphylococcus aureus (MRSA).94,95 Coumarins with alkoxy and 
chloro substituents were reported as effective compounds against Escherichia coli.96 
Furthermore, coumarins act as intermediates for design of several biologically active 
molecules such as chromenes, coumarones, fluorocoumarins and bromocoumarins. 
Chromenes are considered one of the privileged medicinal scaffolds that have attracted a 
great deal of attention.97-110 In addition to their biological activity, certain chromene 
molecules have been used to produce highly effective fluorescent dyes for synthetic fibers, 
daylight fluorescent pigments, electro photographic and electroluminescent devices.111,112 
Due to interest in the anti-microbial activity of coumarins, 5,7 dihydroxy-4-propyl-
coumarin 2.1 was used for the generation of novel derivatives of chromene based 
coumarins and in vitro testing of their antimicrobial and cytotoxic effects. 
 
2.2.1 Study rationale 
Natural products bearing a 4-hydroxy coumarin scaffold were shown to possess 
antimicrobial and cytotoxic activities.91,92,95 Figure 1 shows their chemical structures with 
the similarity analysis and alignment resulting in six-point pharmacophore model that is 
utilized in our design. They overlap in three points and only two others (hydrophobic and 
hydrophilic regions) that occur closely at positions 7 and 8 that might affect activity. It was 
assumed that the hydrophobic region is a key region related to antibacterial and cytotoxic 
activity and hence has been a motivation to synthesize novel derivatives of different  
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lipophilic substituents. In turn, small molecules were designed and tested for potential 
antimicrobial and cytotoxic activities based upon the above natural products’ structure 
analyses. Novobiocin, clorobiocin, and mammea-type coumarin are compared to target 
scaffold. These compounds display pharmacophoric resemblance and key pharmacophoric 
features are highlighted in red or bold lines. 
 
Figure 2.1: Structural similarity of 4-hydroxy coumarin based natural products and target 
scaffold.  
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2.3 Results and Discussion  
2.3.1 Synthesis and Characterization 
A novel series of 8-amino-10-phenyl-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [2,3-f] 
chromene-9-carbonitrile derivatives 2.2(a-j) based 5,7-dihydroxy-4-propy-couromin 2.1 
were synthesized via three component condensation of 5,7 dihydroxy-4-propyl-coumarin 
2.1, benzaldehyde derivatives and malononitrile in an ethanolic piperidine solution under 
reflux (Table 2.1). The common method for the synthesis is based on the use of 
Knoevenagal condensation followed by Michael addition adducts113, as shown in the 
following Schemes 2.1 and 2.2.  
O
OH
HO O
O
OH
OO
CN
H2N
R1
R2
R3
i)  CH2 (CN)2 
ii)  ArCHO
iii)  EtOH / Piperidine
2.1
2.2(a-j)  
Scheme 2.1: Synthesis of 8-amino-10-phenyl-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano 
[2,3-f] chromene-9-carbonitrile derivatives 2.1(a-j). 
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Compound 
No. 
R1 R2 R3 Yield% λabs λem ΦF 
2.2a F H H 98.29 320-409 448 0.20 
2.2b Cl H H 84.23 320-409 450 0.20 
2.2c Br H H 96.07 320-414 450 0.26 
2.2d H Cl H 79.54 322-415 450 0.40 
2.2e H Br H 72.08 322-414 449 0.40 
2.2f H NO2 H 94.30 -- -- -- 
2.2g H OH H 76.47 316-416 448 0.26 
2.2h H H n-butyl 88.76 316-416 451 0.31 
2.2i H H OH 75.29 316-416 452 0.41 
2.2j H H F 80.23 324-417 449 0.54 
    
Table 2.1: The quantum yield (ΦF), wavelength of emission (λem) and absorption (λabs), for 
synthesized derivatives 2.2(a-j)  
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Scheme 2.2: General synthesis and mechanistic pathway of chromene molecules 2.2(a-j) 
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The structures of new chromene molecules 2.2(a-j) were characterized using FT-IR and 
NMR spectroscopic techniques. For instance, the FT-IR spectroscopy showed 
characteristic absorption bands between 2181 and 2200 for the CN groups while the NH2 
stretches were in the range of 3398-3409 cm-1. Moreover, the C=O group displayed bands 
at 1697-1727 cm-1 and the OH bands appeared at 3403-3597 cm-1. The 1H NMR spectra of 
chromene compounds 2.2(a-j) were obtained in DMSO-d6. As anticipated, the methyl 
protons appeared as a triplet set at 0.96-0.98 ppm, while the H10 pyran showed signals at 
4.51-5.18 ppm and the amine protons resonated as a singlet at 6.71-7.11 ppm. The singlet 
at 5.99-6.51 ppm is corresponding to H3, while H6 appeared as singlet between 5.67-6.06 
ppm. The rest of the aromatic protons resonate further downfield in the range of 6.63-8.12 
ppm. In all spectra, the methylene group directly linked to the coumarin moiety showed 
two signals as shown in Figure 2.2 as example of the proton NMR for compound 2.2f.  
 
 
 
 
 
 
 
 
Figure 2.2: 1H NMR of Compound 2.2f 
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The 13C NMR spectra of the new molecules showed that the carbon atoms attached to the 
methyl protons resonate at 14.29-13.28 ppm, while the two methylene carbons resonate at 
23.75-22.06 ppm and 38.18-37.25 ppm. The signal at 37.12-36.37 ppm is corresponding to 
C-4` of the pyran ring, while the quaternary carbon C-2` that is attached to the amine group 
appeared in the range of 57.78-58.34 ppm. The CN carbon resonated further downfield at 
109.84-107.08 ppm and the aromatic CH carbons showed signals between 134.74 and 
114.74 ppm as shown in Figure 2.3. 
 
 
Figure 2.3: 13C NMR spectrum of 2.2f 
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The UV-vis spectra of the new chromene compounds 2.2(a-j) in DMF were found to absorb 
at two distinct peaks around 322 and 410 nm with almost similar shape as shown in Figure 
2.4 
 
Figure 2.4: UV-vis absorption spectra of compounds 2.2(a-j) (10µM) in DMF  
 
Also, fluorescence properties of compounds 2.2(a-j) were examined in DMF solution. Due 
to their conjugation system, all compounds except 2.2f exhibited emission wavelengths 
around 450 nm with excitation λmax at 410 nm, Figure 2.5. In contrast, the presence of nitro 
substituent in 2.2f quenches the fluorescence of this molecule.114,115  
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Figure 2.5: The fluorescence spectra of the new chromene compounds 2.2(a-j) in DMF 
at a concentration of 10 μM.  
 
The fluorescence spectra of these compounds in different solvents such as dimethyl 
sulfoxide (DMSO), N, N-dimethylformamide (DMF), dichloromethane (DCM), 
acetonitrile (ACN), and acetone (Ace) were consistent with the polarity index (PI) for each 
solvent.116 For example, in compound 2.2a the λmax (emission) in DMSO (PI 7.2) was 452 
nm, DMF (PI 6.4) was 450 nm, ACN (PI 5.8) was 442 nm, Ace (PI 5.1) was 441 nm and 
DCM (PI 3.1) was 430 nm (Figure 2.6). 
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Figure 2.6: The fluorescence spectra of compound 2.2a in different solvents (10 μM).  
 
2.3.2 Biological screening 
2.3.2.1 Antimicrobial Screening 
All the newly synthesized compounds 2.2(a-j) were screened for their antibacterial, 
antifungal, and antimycobacterium activities via agar diffusion well method.117 The 
inhibition zones and minimum inhibitory concentrations (MIC) were determined by serial 
dilution method.118 The activity of the synthesized compounds was tested against four 
Gram-positive bacteria including Streptococcus pneumoniae (RCMB 010010), Bacillus 
subtilis (RCMB 010067), Staphylococcus aureus (RCMB 000106), and Methicillin-
Resistant Staphylococcus aureus (MRSA 2658 RCMB), three Gram-negative bacteria 
including Pseudomonas aeruginosa (RCMB 010043), Escherichia coli (RCMB 010052), 
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and Salmonella typhimurium (RCMB 000106), four fungi including Aspergillus fumigatus 
(RCMB 02568), Syncephalastrum racemosum (RCMB 05922), Geotricum candidum 
(RCMB 05097), and Candida albicans (RCMB 05036), and finally, against 
Mycobacterium tuberculosis (RCMB 010094-8). Ampicillin, ciprofloxacin, gentamicin, 
amphotericin B, vancomycin, and isoniazid were used as control drugs.119,120 The observed 
inhibition zone (IZ) and minimum inhibitory concentrations (MIC) of the compounds and 
the reference drugs are given in Table 2.2, 2.3 and presented in Figure 2.7, 2.8. The data 
showed that most of the tested compounds exhibited appreciable bacterial and fungal 
inhibition compared to reference drugs. In general, the synthesized compounds were more 
active against the Gram-negative having IZ values greater than 20. Among the synthesized 
compounds 2.2(e-j) were found to be more effective against E. coli by IZ range 21 to 24 
mm and MIC 0.49 to 3.9 µg/ml compared to reference drugs.  Compounds 2.2(e-g) and 
2.2j were also found to be more active against S.T by IZ 22-26 mm. In the case of 
antibacterial activity against Gram-positive bacteria, most compounds were found to be 
comparably active to reference drugs, having a MIC range 3.9-0.49 µg/mL. In particular, 
2.2g exhibited mild inhibitory activity towards MRSA, IZ 21.3 mm and MIC 1.95 µg/mL. 
The synthesized compounds were moderately or slightly active against the fungal species 
and Mycobacterium tuberculosis (TB). Generally, the investigation of antimicrobial 
activity of the novel derivatives showed more potency than the reference drugs against 
Gram-negative bacteria and mild activity towards Gram-positive bacteria, fungi, and 
mycobacterium. 
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Table 2.2: Antimicrobial activity of synthetic compounds (IZ, diameter (mm)) (1g/mL). 
Compounds 
Inhibition Zone Diameter (mm) 
Gram-positive Gram-negative Fungi 
TB 
S.P B.S S.A MRSA P.A E.C S.T A.F S.R G.C C.A 
2.2a 18.2 17.6 
16.1 NA 15.6 17.1 
17.9 
14.2 NA 13.6 11.4 NA 
2.2b 19.4 18.1 
16.9 NA 16.3 18.2 
18.6 
16.3 NA 14.7 12.6 NA 
2.2c 13.6 16.4 
12.4 NA 13.2 15.7 
17.3 
16.3 NA 18.2 15.4 NA 
2.2d 17.3 17.9 
13.6 NA 11.2 13.4 
16.2 
15.4 NA 14.2 13.6 NA 
2.2e 22.4 21.3 
20.6 18.3 21.3 22.4 
22.6 
20.1 NA 18.2 17.3 NA 
2.2f 24.2 23.6 
21.3 19.6 22.4 24.6 
25.1 
20.3 NA 22.4 19.3 NA 
2.2g 20.4 22.6 
19.8 21.3 23.4 24.9 
26.4 
21.3 NA 24.3 20.8 62.5 
2.2h 18.7 21.3 
20.2 NA 18.3 21.2 
21.9 
18.6 NA 20.1 18.3 NA 
2.2i 21.3 22.1 
20.3 NA 18.4 20.3 
21.2 
20.6 NA 21.2 18.3 NA 
2.2j 21.9 21.2 
20.1 16.3 20.4 21.6 
22.2 
19.6 NA 16.9 16.4 NA 
Ampicillin 23.8 32.4 26.2 - - - - - - - - - 
Ciprofloxacin - - - - 23.4 26.2 27.4 - - - - - 
Gentamicin - - - - 17.3 19.9 22.3 - - - - - 
Amphotericin 
B 
- - - - - - - 23.7 19.7 28.7 25.4 - 
Vancomycin -  - - 20.3 - - - - - - - - 
Isoniazid - - - - - - - - - - - 83.2 
 
Mean zone of inhibition in mm from at least three experiments; (triplicate, mean ± SE, with 
standard errors range 0.01- 0.8). (NA) means no activity. S.P (Streptococcus pneumoniae), 
B.S (Bacillus subtilis), P.A (Pseudomonas aeruginosa), E.C (Escherichia coli), S.T 
(Salmonella typhimurium), A.F Aspergillus fumigatus (RCMB 02568), G.C Geotricum 
candidum (RCMB 05097), S.R Syncephalastrum racemosum (RCMB 05922), and C.A 
Candida albicans (RCMB 05036) and TB Mycobacterium tuberculosis (RCMB 010094-
8) 
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Figure 2.7: Evaluation of Inhibition zone values (IZ) of synthesized derivatives  
Compounds 
Minimal inhibitory concentration (MIC, µg/ml) 
Gram-positive Gram-negative Fungi 
S.P B.S S.A MRSA P.A E.C S.T A.F S.R G.C C.A 
2.2e 1.95 1.95 1.95 7.81 1.95 1.95 0.98 3.9 NA 7.81 15.63 
2.2f 0.49 0.98 1.95 3.9 1.95 0.98 0.49 3.9 NA 1.95 3.9 
2.2g 3.9 1.95 3.9 1.95 0.98 0.49 0.49 1.95 NA 0.49 1.95 
2.2j 1.95 1.95 3.9 3.9 3.9 1.95 1.95 3.9 NA 15.63 31.25 
Ampicillin 0.98 0.24 0.49 - - - - - - - - 
Ciprofloxacin - - - - 0.99 0.59 0.56 - - - - 
Gentamicin - - - - 15.63 3.9 1.95 - - - - 
Amphotericin B - - - - - - - 0.98 3.9 0.49 0.49 
Vancomycin - - - 3.9 - - - - - - - 
Table 2.3: Antimicrobial activity of synthetic compounds (MIC, µg/ml).  
Minimum inhibitory concentration (MIC, mg/mL), results are mean values from at least 
three experiments (triplicate, mean ± SE, with standard errors range 0.1-0.7). (NA) means 
no activity. 
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Figure 2.8: Evaluation of minimum inhibitory concentration values (MIC) of compounds. 
 
2.3.2.2 Cytotoxic screening 
The in vitro cytotoxic activity was performed by MTT assay121,122 against four human 
carcinoma cell lines: Human colon carcinoma (HCT-116), human hepatocellular 
carcinoma (HepG-2), human breast adenocarcinoma (MCF-7), and adenocarcinomic 
human alveolar basal epithelial cell (A-549) cell lines. Doxorubicin was used as a positive 
control, since it has high cytotoxic activity. The inhibitory effects of compounds 2.2(a-j) 
on the growth of the four cell lines are shown in Table 2.4 and Figure 2.9. All compounds 
showed comparable cytotoxicity to the reference drug. Tested compounds exhibited good 
IC50 ranging from 2.9 to 11 µg/mL against HCT-116, while they displayed more inhibitory 
effects against MCF-7 cell line by IC50 0.86 µg/mL than the standard drug. Moreover, they 
showed slightly more activity in case of HepG-2 and A-549 cell lines by IC50 1.5 to 9.3  
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µg/mL range. Further research might lead to improvement in the inhibitory activity, 
especially for compound 2.2e against MCF-7 cell line.  
Compounds 
IC50 (µg/mL) 
HCT-116 MCF-7 HepG-2 A-549 
2.2a 7.91 6.14 4.84 5.24 
2.2b 3.77 2.41 3.97 2.79 
2.2c 15.6 22.2 11.8 8.29 
2.2d 8.29 6.03 2.91 6.08 
2.2e 2.46 0.86 2.19 1.51 
2.2f 2.93 2.67 5.56 3.97 
2.2g 4.79 18.1 4.65 2.96 
2.2h 9.76 9.54 3.3 5.69 
2.2i 11.2 23.6 7.71 7.49 
2.2j 3.03 9.97 9.39 5.67 
Doxorubicin 0.88 1.02 1.19 0.91 
Table 2.4: Cytotoxicity of chromene derivatives against four different cancer cell lines. 
 
Cytotoxicity activity results from at least three experiments (triplicate, mean ±SE, with 
standard errors range 0.02- 0.7). Cytotoxic effects of compounds on colon, breast, liver, 
and epithelial cell lines following exposure to different concentrations of compounds, and 
cell viability was assessed 
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Figure 2.9: Evaluation of cytotoxic activity of target compounds compared to reference 
drug. 
 
2.3.3 Computational studies  
2.3.3.1 Docking studies 
Due to the pharmacological profile as the primary target of the investigation of growth 
inhibition of microorganisms of test compounds and structural similarities for reference 
ligands, molecular modeling studies using the DNA gyrase B subunit were performed, as 
it has been reported as a good target for studying inhibitory activity against these 
bacteria.123 Docking simulations were performed as a primary step to gain insight into the 
plausible mechanism of antibacterial activity of the target compounds. E. coli 
topoisomerase II DNA gyrase B (responsible for the supercoiling activity of DNA in 
bacteria) (PDB code: 1KZN; resolution 2.30 Å) was used by dock module implemented in 
MOE software. 124,125 For this reason, all compounds were docked into active sites of E.  
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coli topoisomerase II DNA gyrase B complexed with the natural inhibitor clorobiocin. The 
least energy binding mode of the compounds has been studied. Figure 2.10 present best 
docking poses for all investigated chromenes inside topoisomerase II DNA gyrase B 
binding pocket. The bound clorobiocin drug displayed specific interaction including 
hydrogen bonding interactions with Asp 73 (1.911 Å), Thr 165 (2.109 Å), Asn 46 (2.034 
Å), Arg 76, and Arg 136 (2.071 Å). 
 
 
Clorobiocin 
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2.2f 
 
 
2.2g 
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2.2i 
 
2.2j 
Figure 2.10 2D binding interaction of target compounds clorobiocin, 2.2f, 2.2g, 2.2i and 
2.2j inside topoisomerase II DNA Gyrase B binding pocket. 
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Table 2.5: Description of the docking data of the selected target compounds, 2.2f, 2.2g, 
2.2h and 2.2j 
Compounds Amino acids (Distance Å) Interaction type  
∆G 
(kcal/mol) 
Asp73 Thr165 Asn46 Arg136   Arg76 
2.2f 
-OH 
(2.7)  
 -OH 
(3.0) 
 =O 
(2.4) 
-NH2 
(2.7)  
- H-bonding 12.3 
2.2g 
-OH 
(3.3) 
 -OH 
(2.48) 
 =O 
(2.5) 
 -NH2 
(2.5)  
-CN 
(3.2) 
H-bonding 13 
2.2h 
-OH 
(3.3) 
 -OH 
(2.5) 
 =O 
(2.4) 
 -NH2 
(2.5)  
-CN 
(3.2) 
H-bonding 11.5 
2.2j 
-OH 
(2.1) 
 -OH 
(2.7) 
=O 
(3.2) 
-NH2 
(2.4) - 
H-bonding 12.1 
Colorobiocin 
-NH 
(1.8) 
-OH 
(H2O) 
(3.2) 
=O  
(2.9) 
=O 
(Chr.) 
(2.9) 
Phenyl 
H-bonding 
(Aromatic) 
12.5 
The data reported in the table are extracted from MOE program showing the corresponding 
amino acids residues in enzyme pocket, corresponding fragments of ligands, interaction 
distances, types of interaction, and their binding energy to some selected drugs compared 
to reference drug. 
 
The results of the docking experiments are presented in Table 2.5. The binding map of the 
compounds in the pocket is explained through four different fragments around the 
chromene scaffold, 2-C=O, 5-OH, 8-NH2, and 9-CN. These fragments form stable 
hydrogen bonding interactions with a panel of corresponding pocket residues: Asn46, 
Thr165, Asp73, Arg136, and Arg76. The substituted 10-phenyl ring is considered to be the 
milestone of activity of the compounds via hydrophobic interactions to different residues  
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Glu50 and Ile90 which contributes considerably to the strength of the binding interactions. 
Table 2.6 summarizes the nature of 10-phenyl substituents regarding their electronic effect 
and contribution to the activity. The substitution at position 3 in the ring positively affects 
the antimicrobial and cytotoxic activity of most compounds, especially those with electron-
withdrawing properties such as halogens, nitro, and hydroxyl groups. This has been 
observed in previous studies126-128 and is clear with derivatives 2.2(d-g), whereas 
compounds with substituents at 2 or 4 position exhibit moderate to low activity regardless 
of their types. The bromo derivatives are in most cases highly active, being clearly more 
effective than chloro and fluoro derivatives, and our results are in agreement with previous 
studies.129 Table 2.6 shows the grouping of target compounds with substitution analysis 
and correlation to their activity. (M) refers to mesomeric effect with positive and negative 
effects while (I) stands for inductive effect with positive and negative effects.  
 
 
 
 
 
 
 
 
 
 
 
57 
 
Table 2.6: Structural and electronic parameters of target compounds and correlation to 
activity. 
 Activity 
Major Electronic 
effect 
  Antibacterial Cytotoxicity 
High 
2.2e,2.2f,2.2g 2.2d,2.2e,2.2f 
  
-I, -M 
3-Br,3-NO2,3-OH 3-Cl,3-Br,3-NO2 
-I, -M, +M -I, -M 
3 Position 
Mild 
2.2a,2.2b,2.2h,2.2i,2.2j 2.2a,2.2b,2.2h,2.2g 
+I, +M, -I 
2-F,2-Cl,4-Butyl,4-
OH,4-F 
2-F,2-Cl, 4-Butyl, 3-OH 
-I, +I, +M +I,+M,-I 
2,4 Positions 
Low 
2.2c,2.2d 2.2c,2.2i 
-I, +M 
2-Br,3-Cl 2-Br, 4-OH 
-I -I,+M 
2,3,4 Positions 
Table shows the grouping of target compounds with substitution analysis and correlation 
to their activity. (M) refers to mesomeric effect with positive and negative effects while (I) 
stands for inductive effect with positive and negative effects. 
 
2.4 Conclusions 
A series of 8-amino-10-phenyl-5-hydroxy-2-oxo-4-propyl-2H, 10H-pyrano[2,3-f] 
chromene-9-carbonitrile derivatives 2.2(a-j) were synthesized by condensation of 
benzaldehyde derivatives and malononitrile in an ethanolic piperidine (Knoevenagal  
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condensation) followed by the electrophilic substitution step of 5,7-dihydroxy-4-propyl-
chromen-2-one (Michael addition adduct). All synthesized compounds were characterized 
by NMR. Fluorescence of the new compounds showed emission peaks at around 450 nm 
with good quantum yields. These novel compounds have potent antibacterial, antifungal, 
and antitumor activities compared to reference drugs. Analysis of the mode of action 
through docking experiments and structure-activity relationship analysis was reported.  
 
2.5 Experimental Section  
2.5.1 Materials and Instrumentation  
Chemicals and solvents were purchased from Sigma-Aldrich (Canada) and Alfa Aesar, and 
were used as received. Compound 2.1 was purchased from Sigma-Aldrich (Canada). 
Melting points were determined in open capillaries using an electrothermal apparatus and 
are uncorrected. The progress of the reactions was monitored using thin layer 
chromatography (TLC) on Merck silica gel 60 F254 plates. Infrared (IR) spectra were 
recorded using Bruker Alpha FT-IR Spectrometer on pressed KBr pellets. 1H-NMR and 
13C-NMR spectra were recorded on a 300 MHz and at 75 MHz, respectively, on a Bruker 
Avance Spectrometer in DMSO-d6 with tetramethylsilane as internal standard. The high 
vacuum for overnight and heat gun were used to removed residual water from the 
compounds. Elemental analyses for C, H and N were performed using an Exeter Analytical, 
Inc. CE-440 Elemental Analyzer. Fluorescence data were acquired on Photon 
Technology International Quantum Master 400 spectrofluorometer.  
 
 
59 
 
The quantum yield of the samples was measurement in 9,10-diphenylanthracene. UV-vis 
absorption measurements were performed using a HP8543 UV-vis 
spectrophotometer. 
 
2.5.2 Biological Studies 
2.5.2.1 Antimicrobial Screening 
The microorganism inoculums were uniformly spread using sterile cotton swabs on a 
sterile Petri dish malt extract agar (for fungi) and nutrient agar (for bacteria). One hundred 
cubic millimeters of each sample was added to each well (10-mm-diameter holes were cut 
in the agar gel, 20 mm apart from one another). The systems were incubated for 24–48 hr. 
at 37 oC (for bacteria) and at 28 oC (for fungi). After incubation, microorganism growth 
was observed. Inhibition zones of the bacterial and fungal growth were measured in 
millimeters. Tests were performed in triplicate. 113,114 
 
2.5.2.2 Cytotoxic Screening 
Human colon carcinoma (HCT-116), human hepatocellular carcinoma (HEPG-2), 
adenocarcinomic human alveolar basal epithelial cell (A-549), and human breast 
adenocarcinoma (MCF-7) cell lines were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). The cells were grown on RPMI-1640 medium 
supplemented with 10% inactivated fetal calf serum and 50 µg/mL gentamycin. The cells 
were maintained at 37 ºC in a humidified atmosphere with 5% CO2 and were subcultured  
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two to three times a week. Potential cytotoxicity of the compounds was evaluated on tumor 
cells using the method of Gangadevi and Muthumary.130 The cells were grown as 
monolayers in growth RPMI-1640. The monolayers of 104 cells adhered at the bottom of 
the wells in a 96-well microliter plate incubated for 24 h at 37 ºC in a humidified incubator 
with 5% CO2. The monolayers were then washed with sterile phosphate buffered saline 
(0.01 M pH 7.2) and simultaneously the cells were treated with 100 µL from different 
dilutions of tested sample in fresh maintenance medium and incubated at 37 ºC. A control 
of untreated cells was made in the absence of tested sample. Positive controls containing 
doxorubicin were also tested as a reference drug for comparison. Six wells were used for 
each concentration of the test sample. Every 24-hour observation under the inverted 
microscope was made. The number of the surviving cells was determined by staining the 
cells with crystal violet followed by cell lysing using 33% glacial acetic acid and the 
absorbance read at 590 nm using a microplate reader (SunRise, TECAN, Inc, USA) 
through mixing121,131. The absorbance values from untreated cells were considered as 100% 
proliferation. The number of viable cells was determined using microplate reader as 
previously mentioned and the percentage of viability was calculated as [1-
(ODt/ODc)]x100% where ODt is the mean optical density of wells treated with the tested 
sample and ODc is the mean optical density of untreated cells. The relation between 
surviving cells and drug concentration was plotted to get the survival curve of each tumor 
cell line after treatment with the specified compound. The 50 % inhibitory concentration  
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(IC50), the concentration required to cause toxic effects in 50% of intact cells, was 
estimated from graphic plots.  
 
2.5.3 Molecular modeling  
The newly synthesized compounds were docked into the crystal structure of E. coli 
topoisomerase II DNA gyrase B (PDB code 1KZN). The MOE software124 was used for 
all docking calculations. The MOE tools package was employed to generate the docking 
input files and to analyze the docking results. All non-polar hydrogens, clorobiocin, and 
crystal water molecules were removed prior to the calculations, the protonation of the 
enzyme was carried out and the structure was energy minimized. In each case, 100 docked 
structures were generated using genetic algorithm searches. The 3D structures of new 
synthesized compounds were drawn in MOE and the protonation of ligands were carried 
out. The energy of compounds was minimized up to 0.05 gradient using GBVI/WSA dG 
force field. These data were saved in database as input file MOE. Heavy atom comparison 
root means square deviations (RMSD values) were calculated and initial ligand binding 
modes were plotted. Protein-ligand interaction plots were generated using MOE 2012.10. 
Quantum mechanical calculations and surface molecular orbitals were generated by 
simulation module in MOE software. 
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2.5.4 Synthesis 
2.5.4.1 General procedure for the synthesis of 8-amino-10-phenyl-5-hydroxy-2 oxo-4-
propyl-2H, 10H-pyrano[2,3-f] chromene-9-carbonitrile derivatives.  
Following similar procedure to the synthesis of chromenes,132 aryl aldehyde (2.3 mmol) 
was added to a solution containing compound 2.1 (2.3 mmol) in 5 mL of ethanol and 
malononitrile (2.3 mmol), along with few drops of piperidine. The reaction mixture was 
stirred at reflux. After completion of the reaction (monitored by TLC), the mixture was 
kept at room temperature and the formed solid product was collected by filtration and 
washed with ethanol and hexane to yield 2.2(a-j).  
2.5.4.2 8-amino-10-(2-fluorophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2a)  
White solid (0.87g, 97%), m.p. 225°C; IR (KBr) cm-1: 3483(OH), 3403 ( NH2), 3055 (Ar-
H), 2966- 2871 (CH), 2199 (CN), 1697 (C=O); 1H NMR (300 MHz, DMSO) δ 10.98 (s, 
1H, OH), 7.27 – 7.22 (m, 1H, Ar-H), 7.16 – 7.09 (m, 3H, Ar-H), 6.97 (s, 2H, NH2), 6.50 
(s, 1H, H3), 6.07 (s, 1H, H6), 4.91 (s, 1H, H10), 3.16-3.09 (m, 1H, CH2), 2.93-2.86 (m, 
1H, CH2), 1.68-1.59 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (75 MHz, 
DMSO) δ 160.47 (C=O), 160.24, 159.19, 158.28, 157.48, 155.71, 148.26, 132.70 (Ar-C), 
130.68, 129.41, 125.42 (Ar-CH), 120.73 (Ar-C), 116.16 (Ar-CH), 111.89 (Ar-CH-3), 
108.13 (CN), 101.71 (Ar-C), 99.68 (Ar-CH-6), 57.14 (C-8), 38.27 (CH2), 31.72 (CH-10),  
23.59 (CH2), 14.15 (CH3); Anal. Calcd for C22H17N2O4F: C, 67.34; H, 4.37; N, 7.14. 
Found: C, 67.05; H, 4.01; N, 7.03. 
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2.5.4.3 8-amino-10-(2-chlorophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene -9-carbonitrile (2.2b)  
White solid (0.78g, 83% ), m.p. 266°C; IR (KBr) cm-1: 3491 (OH), 3405 (NH2), 3063 (Ar-
H), 2971- 2866 (CH), 2193 (CN), 1725 (C=O); 1H NMR (300 MHz, DMSO) δ 10.86 (br. 
s, 1H, OH), 7.40 - 7.37 (m, 1H, Ar-H), 7.27 – 7.17 (m, 2H, Ar-H), 7.05 – 7.02 (m, 1H, Ar-
H), 6.95 (s, 2H, NH2), 6.43 (s, 1H, H3), 6.06 (s, 1H, H6), 5.16 (s, 1H, H10), 3.14-3.06 (m, 
1H, CH2), 2.96- 2.89 (m, 1H, CH2), 1.71-1.56 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 160.31 (C=O), 158.95, 157.58, 155.86, 148.28, 143.17, 
132.80 (Ar-C), 130.97, 130.23, 129.06, 128.46 (Ar-CH), 120.38 (Ar-C), 111.70 (Ar-CH-
3), 108.40 (CN), 101.42 (Ar-C), 99.89 (Ar-CH-6), 57.15 (C-8), 38.06 (CH2), 34.82 (CH-
10), 22.92 (CH2), 14.29 (CH3); Anal. Calcd for C22H17N2O4Cl: C, 64.63; H, 4.19; N, 6.85. 
Found: C, 64.86; H, 4.52; N, 6.52. 
 
2.5.4.4 8-amino-10-(2-bromophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2c)  
Yellowish white solid (0.99g, 95% ), m.p. 282°C; IR (KBr) cm-1: 3501 (OH), 3403 ( NH2), 
3068 (Ar-H), 2962- 2869 (CH), 2200 (CN), 1723 (C=O); 1H NMR (300 MHz, DMSO) δ 
7.56 (d, J = 8.0 Hz, 1H, Ar-H), 7.30-7.26 (m, 1H, Ar-H), 7.13-7.08 (m, 1H, Ar-H), 7.09 
(d, J = 8.0 Hz, 1H, Ar-H), 6.93 (br. s, 2H, NH2), 6.39 (s, 1H, 3), 6.05 (s, 1H, Ar-H6), 5.18 
(s, 1H, 10), 3.14-3.05 (m, 1H, CH2), 2.97-2.90 (m, 1H, CH2), 1.68 – 1.61 (m, 2H, CH2), 
0.98 (t, J = 7.3 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 160.30 (C=O), 159.69, 157.57,  
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156.00, 148.18, 145.06 (Ar-C), 133.33, 131.18, 128.83, 123.36 (Ar-CH), 120.33 (Ar-C), 
111.23 (Ar-CH-3), 108.69 (CN), 101.07 (Ar-C), 99.51 (Ar-CH-6), 57.70 (C-8), 38.23 
(CH2), 36.65 (CH-10), 22.98 (CH2), 14.17 (CH3); Anal. Calcd for C22H17N2O4Br: C, 58.29; 
H, 3.78; N, 6.18. Found: C, 58.38; H, 4.16; N, 5.99. 
 
2.5.4.5 8-amino-10-(3-chlorophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2d)  
Yellowish white solid (0.74g, 79%), m.p. 275°C; IR (KBr) cm-1: 3502 (OH), 3409 (NH2), 
2953- 2875 (CH), 2187 (CN), 1704 (C=O); 1H NMR (300 MHz, DMSO) δ 11.09 (s, 1H, 
OH), 7.34 - 7.28 (m, 2H, Ar-H), 7.16-7.07 (m, 2H, Ar-H), 7.05 (s, 2H, NH2), 6.53 (s, 1H, 
H3), 6.08 (s, 1H, H6), 4.69 (s, 1H, H10), 3.11-3.04 (m, 1H, CH2), 2.98-2.91 (m, 1H, CH2), 
1.65-1.58 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 
160.47 (C=O), 158.42, 15803, 155.62, 148.14, 148.03, 133.79 (Ar-C), 131.77, 127.53, 
127.50, 126.52 (Ar-CH), 120.65 (Ar-C), 111.76 (Ar-CH-3), 109.13 (CN), 102.26 (Ar-C), 
99.84 (Ar-CH-6), 58.00 (C-8), 38.40 (CH2), 37.19 (CH-10), 23.24 (CH2), 14.75 (CH3);  
Anal. Calcd for C22H17N2O4Cl: C, 64.63; H, 4.19; N, 6.85. Found: C, 64.99; H, 4.56; N, 
6.54.  
 
2.5.4.6 8-amino-10-(3-bromophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2e)  
White solid (0.82g, 80% ), m.p. 253°C; IR (KBr) cm-1: 3597 (OH), 3405 (NH2), 3055 (Ar-
H), 2952- 2861 (CH), 2195 (CN), 1721 (C=O); 1H NMR (300 MHz, DMSO) δ 7.38 (d, J  
 
 
65 
 
= 8.0 Hz, 1H, Ar-H), 7.30-7.24 (m, 2H, Ar-H), 7.14 (d, J = 7.2 Hz 1H, Ar-H), 6.99 (s, 2H, 
NH2), 6.34 (s, 1H, H3), 5.96 (s, 1H, H6), 4.66 (s, 1H, H10), 3.12-2.99 (m, 1H, CH2), 2.97-
2.85 (m, 1H, CH2), 1.65 – 1.58 (m, 2H, CH2), 0.96 (t, J = 7.3 Hz, 3H, CH3); 13C NMR (75 
MHz, DMSO) δ 160.88 (C=O), 157.69, 156.29, 149.31, 148.11 (Ar-C), 131.94, 130.54, 
127.35, 122.76 (Ar-CH), 120.76 (Ar-C), 111.18 (Ar-CH-3), 109.58 (CN), 100.52 (Ar-C), 
100.60 (Ar-CH-6), 58.29 (C-8), 38.32 (CH2), 37.13 (CH-10), 22.95 (CH2), 14.57 (CH3); 
Anal. Calcd for C22H17N2O4Br: C, 58.29; H, 3.78; N, 6.18. Found: C, 58.69; H, 4.11; N, 
6.29.  
 
2.5.4.7 8-amino-10-(3-nitrophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2f)  
White solid (0.90g, 94% ), m.p. 226°C; IR (KBr) cm-1: 3495 (OH), 3404  (NH2), 3067 (Ar-
H), 2969- 2878 (CH), 2200 (CN), 1727 (C=O), 1531, 1354 (NO); 1H NMR (300 MHz, 
DMSO) δ 8.10- 8.06 (m, 1H, Ar-H), 7.98 (br. s, 1H, Ar-H), 7.63 – 7.59 (m, 2H, Ar-H), 
7.11 (s, 2H, NH2), 6.46 (s, 1H, H3), 6.04 (s, 1H, H6), 4.87 (s, 1H, H10), 3.14-3.05 (m, 1H, 
CH2), 2.97-2.87 (m, 1H, CH2), 1.67 – 1.60 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 160.78 (Ar-C), 160.28 (C=O), 159.22, 157.42, 156.05, 
148.78, 148.28, 147.91 (Ar-C), 134.86, 131.01, 122.74, 122.31 (Ar-CH), 120.69 (Ar-C), 
111.62 (Ar-CH-3), 108.57 (CN), 102.01 (Ar-C), 99.92 (Ar-CH-6), 58.07 (C-8), 38.45 
(CH2), 37.14 (CH-10), 23.54 (CH2), 14.91 (CH3); Anal. Calcd for C22H17N3O6: C, 63.01; 
H, 4.09; N, 10.02. Found: C, 63.32; H, 4.34; N, 9.69.  
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2.5.4.8 8-amino-10-(3-hydroxyphenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [2,3-f] 
chromene-9-carbonitrile (2.2g)  
White solid (0.75g, 84%), m.p. 213°C; IR (KBr) cm-1:  3493 (OH), 3399  (NH2), 3067 (Ar-
H), 2942- 2865 (CH), 2181 (CN), 1711 (C=O); 1H NMR (300 MHz, DMSO) δ 7.02 (t, J = 
8.4 Hz, 1H, Ar-H), 6.89 (s, 2H, NH2), 6.60-6.52 (m, 3H, Ar-H), 6.38 (s, 1H, 3), 5.96 (s, 
1H, Ar-H6), 4.54 (s, 1H, 10), 3.08-2.99 (m, 1H, CH2), 2.86-2.79 (m, 1H, CH2), 1.65–1.58 
(m, 2H, CH2), 0.97 (t, J = 7.3 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 161.10 (C=O), 
160.67, 158.21, 157.52, 155.94, 148.25, 147.66 (Ar-C), 130.11 (Ar-CH), 121.04 (Ar-C), 
118.48, 114.74, 114.15 (Ar-CH), 110.50 (Ar-CH-3), 109.71 (CN), 100.74 (Ar-C), 99.85 
(Ar-CH-6), 58.95 (C-8), 38.20 (CH2), 36.93 (CH-10), 23.02 (CH2), 14.18 (CH3); Anal. 
Calcd for C22H18N2O5: C, 67.69; H, 4.65; N, 7.18. Found: C, 67.91; H, 4.90; N, 7.66.  
 
2.5.4.9 8-amino-10-(4-butylphenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [ 2,3-f] 
chromene-9-carbonitrile (2.2h) 
White solid (0.87g, 88%), m.p. 235°C; IR (KBr) cm-1: 3499 (OH), 3404 (NH2), 3067 (Ar-
H), 2958- 2859 (CH), 2196 (CN), 1722 (C=O); 1H NMR (300 MHz, DMSO) δ 11.02 (br.s, 
1H, OH), 7.09 (d, J = 8.1 Hz, 2H, Ar-H), 7.01 (d, J = 8.1 Hz, 2H, Ar-H), 6.96 (s, 2H, NH2), 
6.53 (s, 1H, H3), 6.06 (s, 1H, H6), 4.61 (s, 1H, H10), 3.4-3.2 (m, 2H, CH2), 3.16- 3.06 (m, 
1H, CH2), 2.96 – 2.87 (m, 1H, CH2), 1.62 (q, J = 7.2 Hz, 2H, CH2 ), 1.52 (q, J = 7.2 Hz, 
2H, CH2 ), 1.32-1.27 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3), 0.87 (t, J = 7.3 Hz, 3H, 
CH3); 
13C NMR (75 MHz, DMSO) δ 160.50 (C=O), 160.24, 158.25, 157.49, 155.50,  
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148.05, 143.26, 141.42 (Ar-C), 129.23, 127.57 (Ar-CH), 120.94 (Ar-C), 111.94 (Ar-CH-
3), 109.87 (CN), 101.88 (Ar-C), 99.81 (Ar-CH-6), 58.84 (C-8), 37.99 (CH2), 36.65 (CH-
10), 35.32 (CH2), 34.09 (CH2), 31.60 (CH2), 22.69 (CH2), 14.62 (CH3), 14.14 (CH3); Anal. 
Calcd for C26H26N2O4: C, 72.54; H, 6.09; N, 6.51. Found: C, 72.57; H, 6.24; N, 6.30.  
 
2.5.4.10 8-amino-10-(4-hydroxyphenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyra-non [2, 
3-f] chromene-9-carbonitrile (2.2i) 
White solid (0.71g, 81% ), m.p. 209°C; IR (KBr) cm-1: 3495 (OH), 3400 (NH2), 2958- 
2867 (CH), 2194 (CN), 1717 (C=O); 1H NMR (300 MHz, DMSO) δ 10.94 (s, 1H, OH), 
9.29 (s, 1H, OH), 6.93 (d, J = 8.4 Hz, 2H, Ar-H), 6.90 (s, 2H, NH2), 6.66 (d, J = 8.4 Hz, 
2H, Ar-H), 6.52 (s, 1H, H3), 6.09 (s, 1H, H6), 4.53 (s, 1H, H10), 3.13-3.05 (m, 1H, CH2), 
2.95-2.86 (m, 1H, CH2), 1.66-1.59 (m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR 
(75 MHz, DMSO) δ 161.11 (C=O), 160.86, 157.95, 156.67, 147.96, 137.23, 121.53 (Ar-
C), 128.79, 115.72 (Ar-CH), 111.58 (CN), 107.74 (Ar-CH-3), 100.34 (Ar-CH-6), 98.10 
(Ar-C), 59.48 (C-8), 38.18 (CH2), 36.37 (CH-10), 23.11 (CH2), 14.27 (CH3); Anal. Calcd 
for C22H18N2O5: C, 67.69; H, 4.65; N, 7.18. Found: C, 67.26; H, 4.34; N, 7.50.  
  
2.5.4.11 8-amino-10-(4-fluorophenyl)-5-hydroxy-2-oxo-4-propyl-2H,10H-pyrano [2,3-f] 
chromene-9-carbonitrile (2.2j)  
Yellowish white solid (0.71g, 79%), m.p. 197.2°C; IR (KBr) cm-1: 3403 (OH), 3398 (NH2),  
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3055 (Ar-H), 2966- 2932 (CH), 2189 (CN), 1721 (C=O); 1H NMR (300 MHz, DMSO) δ 
7.17- 7.11 (m, 4H, Ar-H), 6.97 (s, 2H, NH2), 6.48 (s, 1H, H3), 6.04 (s, 1H, H6), 4.66 (s, 
1H, H10), 3.11–3.04 (m, 1H, CH2), 2.93-2.89 (m, 1H, CH2), 1.66 – 1.58 (m, 2H, CH2), 
0.97 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 163.38 (C=O), 160.45, 158.67, 
157.52, 155.68, 147.90, 142.28 (Ar-C), 129.77, 129.61 (Ar-CH), 120.85 (Ar-C), 116.21, 
115.94 (Ar-CH), 111.71 (Ar-CH-3), 109.44 (CN), 101.75 (Ar-C), 99.84 (Ar-CH-6), 58.62 
(C-8), 38.21 (CH2), 36.50 (CH-10), 22.84 (CH2), 14.30 (CH3);  Anal. Calcd for 
C22H17N2O4F: C, 67.34; H, 4.37; N, 7.14. Found: C, 66.98; H, 4.61; N, 6.94.  
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Chapter Three: Synthesis, Antimicrobial, Cytotoxicity Behavior and Structure 
Activity Relationships of Chromene Based Flavanone Moiety.  
 
3.1 Synopsis  
Several new 8-amino-10-phenyl-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-diydro-2H, 
10H-pyrano [2,3-f] chromene derivatives 3.2(a-g) were synthesized in good yields. The 
structures of these derivatives were established on the basis of IR, 1H NMR, 13C NMR, 1H-
1H COSY, HSQC, HMBC and elemental analysis. All new synthesized compounds were 
evaluated for in vitro antimicrobial and cytotoxicity activities. Their antimicrobial activity 
was investigated and tested against seven human pathogen Gram-positive and Gram-
negative bacteria: Bacillus cereus, Staphylococcus aureus, Escherichia coli, Pseudomonas 
aeruginosa, four fungi: Aspergillus niger, Aspergillus flavus, Fusarium oxisporum, 
Rhizopus stolonifer and one mycobacterium, Mycobacterium tuberculosis, using agar well 
diffusion method and minimum inhibitory concentrations were reported. All of the new 
derivatives exhibited significant potent antimicrobial activities against most bacterial 
strains compared to reference drugs. The results of antibacterial assay revealed that the 
compounds 3.2a, 3.2b and 3.2(e-g) exhibited the highest inhibitory activity against 
Pseudomonas aeruginosa and E. coli by IZ range 18.3 to 24.6 mm and MIC 0.49 to 3.9 
µg/ml compared to reference drugs. Compounds 3.2a, 3.2b and 3.2e were found to be more 
effective against Salmonella typhimurium by IZ 23.4-26.4 mm.  
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The antibacterial activity of most compounds was found to be comparably active to 
reference drugs against Gram-positive bacteria. Compound 3.2c did not show any 
antimicrobial activity against all the tested bacteria, fungi and TB. Moreover, the cytotoxic 
activity was also evaluated against four different human carcinoma cell lines: human colon 
carcinoma (HCT-116), human hepatocellular carcinoma (HepG-2), human breast 
adenocarcinoma (MCF-7), and adenocarcinoma human alveolar basal epithelial cell (A-
549) cell lines, and exhibited good cell growth inhibitory activity against HCT-116 cell 
line (IC50= 1.08-1.48 µg/ml). The molecular modeling results showed binding interaction 
of synthesized compounds 3.2a, 3.2b, 3.2d, 3.2e and kaempferol as reference drug in the 
active site of Gyres B. 
 
3.2 Introduction 
Substantial increasing of resistance of microorganisms against used antimicrobial agents is 
one of major concern among scientists and clinicians worldwide. Moreover, the pathogenic 
viruses, bacteria, fungi, and protozoa become more and more difficult to treat with the 
already existing drugs.133 To overcome the drawbacks of the current antimicrobial drugs 
and to obtain more efficacious drugs, an antimicrobial drug having a novel mode of action 
should be developed.134 The abuse of synthetic antibiotics has contributed to the increased 
incidence of bacterial resistance to available antibacterial agents, resulting in an urgent 
need for natural antimicrobials.135  
 
 
71 
 
Plant-derived flavonoids are a large group of naturally occurring phenyl chromones widely 
distributed in edible plants and found in fruits, vegetables, tea, and wine.136,137 They have 
been shown to have a wide range of biological activities, including antiallergic, 
antibacterial, antidiabetic, anti-inflammatory, antiviral, antiproliferative, antimutagenic, 
antithrombotic, anticarcinogenic, hepatoprotective, oestrogenic, insecticidal, and 
antioxidant activities.138,139 The antibacterial activities of flavonoids have been reported to 
be related to their chemical structures.139-142 However, the quantitative structure activity 
relationship (QSAR) for flavonoids as antibacterial agents is gaining interest by 
quantitatively correlating the molecular structures or properties with variation in biological 
activity.143,144 Most of the interesting pharmacological properties of flavonoids is the 
anticancer activity145, which reported different mechanisms of the effects of flavonoids 
aiding in the prevention of cancer growth through their ability to work as anti-oxidants,69-
71 enzyme inhibitors146 and growth regulators.147 Flavanones, 2-phenylchroman-4-one, 
belong to the family of flavonoids, many of which are produced as secondary metabolites 
in the plant kingdom. They have three-ring skeletons, C6-C3-C6, and the rings are referred 
to as A-, C-, and B-rings, respectively. Their functional groups are attached to the main 
skeleton through oxygen or carbon linkages.148 The biological activities of flavonoids 
depend on the degree of condensation in their structures and the position and number of 
substitutions, such as hydroxy groups, glucosides, isoprenyl units, homodimers, and 
heterodimers.149  
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Flavanones compared to flavanone, 2-phenyl-4H-chromen-4-one, have more molecular 
flexibility due to the absence of a carbon–carbon double bond in the C-ring. In our previous 
studies, we found that methoxy or hydroxy substituent at C-7 position of flavanone resulted 
in better inhibitory effects on HCT116 human colon cancer cell lines.150 Based on this 
result, we tried to design flavanone derivatives with bulkier substituents at C-7 position 
and elucidate their inhibitory effects. Since the anti-cancer activity of naringenin, 4',5,7-
trihydroxyflavanone 3.1 against colon cancer cells has been reported, several flavanone 
derivatives were designed from naringenin.151 In addition, it was found that the naringenin 
plays a key role as an estrogenic substance in humans and as an endogenous regulator in 
plants.152 Various flavonoid derivatives modified at C-7 position have been reported, but 
in flavanone, especially naringenin, derivatives modified at position 7 have rarely been 
studied.153, 154 Naringenin derivatives designed in this study have a common moiety formed 
between 7-OH and 8-H positions resulting NH2-CC-CN fragment which may affect their 
biological activity. 
 
3.3 Results and Discussion 
3.3.1 Synthesis and Characterization  
All compounds 3.2(a-g) were synthesized according to the steps outline in Scheme 3.1. 
The chromene derivatives based on 4`,5,7-trihydroxyflavanone 3.1 were prepared by 
condensation between 4`,5,7-trihydroxyflavanone, malononitrile or ethylcyanoacetate and  
aromatic aldehydes in the presence of piperidine in ethanol under reflux (Table 3.1). 
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i)  CH2 (CN)2 
ii)  ArCHO 
iii)  EtOH / Piperidine
OO
OH O
R2H2N
R1
OH
OHO
OH O
OH
3.2(a-g)3.1  
Scheme 3.1: Synthesis of 8-amino-10-phenyl-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-
diydro-2H,10H-pyrano[2,3-f] chromene derivatives 3.2(a-g). 
Compound No. R1 R2 Yield% 
3.2a CN 2-ClC6H5 89.51 
3.2b CN 2-FC6H5 71.51 
3.2c CN 3-BrC6H5 77.42 
3.2d CN 4-C(CH3)3C6H5 84.36 
3.2e CN C4H4S 88.31 
3.2f CN 4-FC6H5 68.35 
3.2g COOEt 3-NO2C6H5 74.58 
Table 3.1: The yields of new synthesized derivatives 3.2(a-g). 
 
The first step of this multicomponent process begins with Knoevenagel condensation and 
then followed by Michael addition adducts113, as shown in the following Scheme 3.2. 
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Scheme 3.2: General synthesis and mechanistic pathway of chromene molecules 3.2(a-g) 
 
The newly synthesized derivatives were confirmed by the various analytical techniques 
such as FT-IR, 1H NMR, 13C NMR, COSY, HMBC, HSQC and elemental analysis. FT-IR 
spectroscopy showed characteristic absorption bands between 2178 and 2207 for the CN 
groups while the NH2 stretches were in the range of 3381-3402 cm
-1. Moreover, the C=O 
group displayed bands at 1634-1686 cm-1 and the OH bands appeared at 3477-3634 cm-1. 
In the 1H NMR spectra of synthesized derivatives 3.2(a-g) were obtained in DMSO-d6, the 
H2 signal showed as a doublet of doublets around 5.07-5.64 ppm. The resonances of the 
diastereotopic H3ax and H3eq protons appeared approximately at 3.34-3.51 and 2.72-2.83 
ppm as two doublets of doublets. The H3ax and H3eq of chromane ring are coupled with  
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a constant of 17.1-17.6 Hz related to the geminal coupling. The value of coupling constant 
between H2 and H3ax is too large (J=12.2-13.5 Hz) which can only arise from a trans-
diaxial coupling, thus H2 is axial and the aryl group was linked to H2 has equatorial 
orientation. As anticipated, the hydroxyl group linked to C5 appeared as a singlet set at 
11.9-12.5 ppm and the C4`-OH occurred approximately at 9.62-9.63 ppm, while the H10 
pyran showed signals at 4.46-5.08 ppm and amine protons resonated at 7.03-7.79 ppm. The 
singlet at 6.21-6.27 ppm is corresponding to H6, while aromatic protons resonate further 
downfield between 6.74 and 8.08 ppm. Figure 3.1 shows one example of the proton NMR 
for compound 3.2a. In compound 3.2g spectrum, the methyl protons appeared at 0.98 ppm 
as triplet, while -OCH2CH3 showed at 3.81 to 4.03 ppm. 
 
Figure 3.1: 1H NMR of Compound 3.2a 
 
 
76 
 
The 13C NMR spectra of the new molecules showed signals at 78.8-80.2 ppm and 41.7-
43.4 ppm represent C-2 and C-3 respectively, C-2 being assigned the lower field signal 
because it is oxygenated, while C-6 signal showed at 94.8-96.8 ppm. The B ring carbons, 
C-2`and C-6` presented at 128.5-129.5 ppm, while C-3` and C-5` showed at 115.9-116.1 
ppm. The C-4` which is connected to hydroxyl group appeared at 157.9-158.9 ppm and the 
signal at 128.4-132.8 ppm is ascribed to C-1`. The signal at 30.3-36.2 ppm corresponds to 
C-10 of the pyran ring, while the quaternary carbon C-8 that is attached to amine group 
appeared in the range of 159.3-161.9 ppm. The cyanide functionality resonated further 
downfield at 119.7-121.0 ppm and the aromatic carbons showed signals between 162.9 and 
102.8 ppm, with an additional signal for C=O of flavanone moiety at 198.0-198.9 ppm 
(Figure 3.2) The carbon atom attached to the methyl group in compound 4.2g resonated at 
15.0 ppm, while the -OCH2CH3 carbons appeared at 59.8 ppm and signal for (C=O ester) 
showed at 168.7 ppm. 
 
Figure 3.2: DEPTQ135 13C NMR of Compound 3.2a 
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3.3.2 Biological Screening   
3.3.2.1 Antimicrobial Screening 
The new synthesized compounds 3.2(a-g) were screened in vitro for their antibacterial, 
antifungal, and antimycobacterium activities via agar diffusion well method.117 The 
activity of the synthesized compounds was tested against four Gram-positive bacteria 
including Streptococcus pneumoniae (RCMB 010010), Bacillus subtilis (RCMB 010067), 
Staphylococcus aureus (RCMB 000106), and Methicillin-Resistant Staphylococcus aureus 
(MRSA 2658 RCMB), three Gram-negative bacteria including Pseudomonas aeruginosa 
(RCMB 010043), Escherichia coli (RCMB 010052), and Salmonella typhimurium (RCMB 
000106), four fungi including Aspergillus fumigatus (RCMB 02568), Syncephalastrum 
racemosum (RCMB 05922), Geotricum candidum (RCMB 05097), and Candida albicans 
(RCMB 05036), and finally, against Mycobacterium tuberculosis (RCMB 010094-8). 
Ampicillin, Gentamicin, amphotericin B, vancomycin, and isoniazid were used as control 
drugs.119, 120 The inhibition zones and minimum inhibitory concentrations (MIC) were 
determined by serial dilution method. The values of inhibition zone (IZ) and minimum 
inhibitory concentrations (MIC) of the target compounds against P.A and E. coli revealed 
that derivatives 3.2a-b and 3.2(d-g) showed the highest inhibitory activity by IZ range 18.3 
to 24.6 mm and MIC 0.49 to 3.9 µg/ml compared to reference drugs, while the results of 
inhibition zone (IZ) and minimum inhibitory concentrations (MIC) were displayed in 
Table 3.2, 3.3 and presented in Figure 3.3, 3.4. Compounds 3.2a, 3.2b and 3.2e were found 
to be more effective against S.T by IZ 23.4-26.4 mm. The antibacterial activity of most  
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compounds were found to be comparably active to reference drugs against gram-positive 
bacteria, having MIC range 0.49 to 3.9 µg/ml. Compounds 3.2b and 3.2e exhibited mild 
inhibitory activity against MRSA by IZ 21.3-20.6 mm and MIC 1.95-3.9 µg/ml. Most of 
the synthesized derivatives were slightly active against the TB and fungal species. 
Compound 3.2e exhibited moderately active to isoniazid. On the other hand, compound 
3.2c did not show any antimicrobial activity against all the tested bacteria, fungi and TB. 
In general, the antimicrobial activity of the new derivatives showed more potency than the 
reference drugs against Gram-negative bacteria and mild activity towards Gram-positive 
bacteria, fungi, and TB.  
Compounds 
Inhibition Zone Diameter (mm) 
Gram-positive Gram-negative Fungi 
TB 
S.P B.S S.T MRSA P.A E.C S.T A.F S.R G.C C.A 
3.2a 21.3 23.2 22.4 18.6 20.3 22.4 23.4 21.3 NA 23.1 20.4 53.1 
3.2b 22.6 26.4 24.6 20.6 22.6 24.6 26.3 23.4 NA 25.2 22.4 72.3 
3.2c NA NA NA NA NA NA NA NA NA NA NA NA 
3.2d 18.6 21.3 21.5 17.9 19.3 21.4 21.9 18.3 NA 20.9 20.1 56.3 
3.2e 23.1 26.4 24.2 21.3 21.3 24.2 26.4 22.3 NA 26.4 21.3 80.1 
3.2f 17.2 18.9 20.3 16.8 18.3 20.3 21.5 19.6 NA 18.4 18.1 41.2 
3.2g 19.4 21.5 21.9 18.4 18.9 20.1 21.2 19.3 NA 21.2 20.4 67.3 
Ampicillin 23.8 32.4 26.2 - - - - - - - - - 
Gentamicin - - - - 17.3 19.9 22.3 - - - - - 
Ciprofloxacin - - - - 23.4 26.2 27.4 - - - - - 
Amphotericin 
B 
- - - - - - - 23.7 19.7 28.7 25.4 - 
Vancomycin -  - - 20.3 - - - - - - - - 
Isoniazid - - - - - - - - - - - 83.2 
Table 3.2: Antimicrobial activity of synthetic compounds (IZ, diameter (mm)) (1 mg/mL). 
Mean zone of inhibition in mm from at least three experiments; (triplicate, mean ± SE, with 
standard errors range 0.01- 0.8). (NA) means no activity. S.P (Streptococcus pneumoniae),  
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B.S (Bacillus subtilis), P.A (Pseudomonas aeruginosa), E.C (Escherichia coli), S.T 
(Salmonella typhimurium), A.F Aspergillus fumigatus (RCMB 02568), G.C Geotricum 
candidum (RCMB 05097), S.R Syncephalastrum racemosum (RCMB 05922), and C.A 
Candida albicans (RCMB 05036) and TB Mycobacterium tuberculosis (RCMB 010094-
8). 
 
Figure 3.3: Evaluation of Inhibition zone values (IZ) of synthesized derivatives.  
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Table 3.3: Antimicrobial activity of synthetic compounds (MIC, µg/ml). 
Compounds 
Minimal inhibitory concentration (MIC, µg/ml) 
TB 
Gram-positive Gram-negative Fungi 
S.P B.S 
 
S.A MRSA P.A E.C 
 
S.T A.F S.R G.C C.A  
3.2a 1.95 0.98 1.95 7.81 3.9 1.95 0.98 1.95 NA 0.98 3.9 31.2 
3.2b 0.98 0.49 0.49 3.9 0.98 0.49 0.49 0.98 NA 0.49 0.98 15.6 
3.2d NA NA NA NA NA NA NA NA NA NA NA 31.2 
3.2e 0.98 0.49 0.98 1.95 1.95 0.98 0.49 0.98 NA 0.49 1.95 3.9 
3.2f 15.63 3.9 3.9 15.63 7.81 3.9 0.98 3.9 NA 7.81 7.81 62.5 
3.2g NA NA NA NA NA NA NA NA NA NA NA 7.8 
Ampicillin 0.98 0.24 0.49 - - - - - - - - - 
Ciprofloxacin - - - - 0.99 0.59 0.56 - - - - - 
Isoniazid - - - - - - - - - - - 1.95 
Amphotericin B - - - - - - - 0.98 3.9 0.49 0.49 - 
Vancomycin - - - 3.9 - - - - - - - - 
Minimum inhibitory concentration (MIC, mg/mL), results are mean values from at least 
three experiments (triplicate, mean ± SE, with standard errors range 0.1-0.7). (NA) means 
no activity. 
 
Figure 3.4: Evaluation of minimum inhibitory concentration values (MIC) of compounds.  
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3.3.2.2 Cytotoxic Screening 
 
The in vitro cytotoxic activity of the synthesized derivatives 3.2(a-g) was tested against 
four human carcinoma cell lines including human colon carcinoma (HCT-116), human 
hepatocellular carcinoma (HepG-2), human breast adenocarcinoma (MCF-7), and 
adenocarcinoma human alveolar basal epithelial cell (A-549) cell lines. The assay was 
performed by MTT assay121,122 Doxorubicin was used as reference drug. The inhibitory 
activities (IC50) are given in Table 3.4 and Figure 3.5. Compounds 3.2b and 3.2(d-g) 
showed good cell growth inhibitory activity against HCT-116 cell line (IC50= 1.08-1.48 
µg/ml). The IC50 values of test compounds against HepG-2 and A-549 cells revealed that 
compound 3.2e had comparable activity respect to the reference drug. By comparing the 
inhibitory activity of compounds with that of doxorubicin against MCF-7 cell line, most 
compounds were less active than the doxorubicin. Further research might lead to 
improvement in the inhibitory activity especially for compound 3.2e against HCT-116 cell 
line.  
Compounds 
IC50 (µg/mL) 
HCT-116 MCF-7 HepG-2 A-549 
3.2a 6.09 16.1 18.2 11.6 
3.2b 1.41 5.56 5.26 4.79 
3.2c 7.48 9.4 4.38 2.81 
3.2d 1.33 2.9 3.07 3.01 
3.2e 1.08 2.42 2.04 1.39 
3.2f 1.13 3.53 29.2 9.23 
3.2g 1.48 12.2 2.58 2.63 
Doxorubicin 0.88 1.02 1.19 0.91 
Table 3.4: Cytotoxicity of chromene derivatives against four different cancer cell lines. 
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Cytotoxicity activity results from at least three experiments (triplicate, mean ±SE, with 
standard errors range 0.02- 0.7). Cytotoxic effects of compounds on colon, breast, liver, 
and epithelial cell lines following exposure to different concentrations of compounds, and 
cell viability was assessed 
 
Figure 3.5: Evaluation of cytotoxic activity of target compounds compared to reference 
drug. 
 
2.3.3 Computational studies  
3.3.3.1 Docking studies  
Docking study was performed for tested compounds, 3.2a, 3.2b, 3.2d and 3.2e in order to 
investigate the possible interactions with Gyrase B (GyrB43) from E. coli (PDB code: 
4PRV; resolution 2.00 Å) by dock module implemented in MOE software. It has been 
reported as a good target for studying antibacterial activity.155  
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Figure 3.6 present best docking poses for new synthesized chromenes inside gyrase B 
binding pocket. The bound kaempferol displayed interaction including hydrogen bonding 
interactions with Ala 100 (2.29 Å), Lys 103 (1.94, 2.16 A) for hydroxyl group linked to C5 
and carbonyl group. The results of the docking experiments are presented in Table 3.5. 
The binding map of the compounds in the pocket is explained through different fragments, 
4-C=O, 5-OH, 4`-OH, 8-NH2, 3-CH, 9-CN and phenyl. These fragments form stable 
hydrogen bonding interactions with a panel of corresponding pocket residues: Ala 100, Glu 
50, Asp 73, Lys 103, Gly 77, Gly 102 and Pro 79. 
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3.2d 
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3.2e 
Figure 3.6: 2D and 3D binding interaction of target compounds; naringenin, 3.2a, 3.2b 
3.2d and 3.2e inside DNA gyrase enzyme subunit B 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
Table 3.5: Description of the docking data of the selected target compounds, 3.2e, 3.2b 
3.2d and 3.2a 
Compound No. 3.2a 3.2b 3.2d 3.2e 
Kaempferol 
 
Amino acid 
(Distance Å) 
Ala 100 -NH2 (2.1) -NH2 (1.8) - -NH2 (1.7) -OH (2.2) 
Glu 50 -CH (3.2) -CH (3.2)  CH (3.3) - 
Asp 73 -OH (1.8) -OH (1.8) - OH (1.8) - 
Lys 103 -CN (2.2) -CN (2.5)- - -CN (2.4) 
-OH, C=O 
(1.94, 2.16) 
Gly 77 - - -C=O (1.7) - - 
Gly 102 - - -CN (1.79) - - 
Pro 79 - - Phenyl (2.7) - - 
Asn 46 - - - - - 
Interaction type H-bonding H-bonding 
H-bonding 
(Aromatic) 
H-
bonding 
H-bonding 
∆G 
(kcal/mol) 
-14.10 -15.65 -15.35 -16.00 -12.02 
The data reported in the table are extracted from MOE program showing the corresponding 
amino acids residues in enzyme pocket, corresponding fragments of ligands, interaction 
distances, types of interaction, and their binding energy to some selected drugs compared 
to reference drug. 
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3.4 Conclusions 
The present study describes the synthesis of new 8-amino-10-phenyl-5-hydroxy-2-(4-
hydroxyphenyl)-4-oxo-3,4-diydro-2H,10H-pyrano [2,3-f] chromene derivatives 3.2(a-g) 
and evaluation of their antimicrobial activity and cytotoxic effects. These target 
compounds were synthesized by condensation of benzaldehyde derivatives and 
malononitrile in an ethanolic piperidine (Knoevenagel condensation) followed by the 
electrophilic substitution step of 4`5,7-trihydroxy-flavanone (Michael addition adduct). 
The structures of the synthesized compounds were established from spectroscopic data. 
The results of antibacterial assay revealed that the compounds 3.2a, 3.2b and 3.2(d-g) 
exhibited the highest inhibitory activity against P.A and E. coli by IZ range 18.3 to 24.6 
mm and MIC 0.49 to 3.9 µg/ml compared to reference drugs. Compounds 3.2a, 3.2b and 
3.2e were found to be more effective against S.T by IZ 23.4-26.4 mm. The antibacterial 
activity of most compounds was found to be comparably active to reference drugs against 
Gram-positive bacteria. Moreover, the cytotoxic activity was also evaluated against four 
different human carcinoma cell lines. Most of compounds have good inhibitory activity 
against HCT-116 cell line (IC50= 1.08-1.48 µg/ml). Finally, compound 3.2c showed no any 
antimicrobial activity against all the tested bacteria, fungi and TB. The molecular modeling 
results showed binding interaction of new synthesized derivatives in the active site of 
Gyrase B. 
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3.5 Experimental Section   
3.5.1 Materials and Instrumentation  
Chemicals and solvents were purchased from Sigma-Aldrich (Canada) and Alfa Aesar, and 
were used as received. Compound 3.1 was purchased from Sigma-Aldrich (Canada). 
Melting points were determined in open capillaries using an electrothermal apparatus and 
are uncorrected. The progress of the reactions was monitored using thin layer 
chromatography (TLC) on Merck silica gel 60 F254 plates. Infrared (IR) spectra were 
recorded using Bruker Alpha FT-IR Spectrometer as pressed KBr pellets. 1H-NMR and 
13C-NMR spectra were recorded on a 300 MHz and at 75 MHz, respectively, on a Bruker  
Avance Spectrometer in DMSO-d6 with tetramethylsilane as internal standard. The high 
vacuum for overnight and heat gun were used to removed residual water from the 
compounds. Elemental analyses for C, H and N were performed using an Exeter Analytical, 
Inc. CE-440 Elemental Analyzer.  
 
3.5.2 Biological Studies  
3.5.2.1 Antimicrobial Screening 
The microorganism inoculums were uniformly spread using sterile cotton swabs on a 
sterile Petri dish malt extract agar (for fungi) and nutrient agar (for bacteria). One hundred 
cubic millimeters of each sample was added to each well (10-mm-diameter holes were cut 
in the agar gel, 20 mm apart from one another). The systems were incubated for 24–48 hr. 
at 37oC (for bacteria) and at 28oC (for fungi).  
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After incubation, microorganism growth was observed. Inhibition zones of the bacterial 
and fungal growth were measured in millimeters. Tests were performed in triplicate. 113,114 
 
3.5.2.2 Cytotoxic Screening 
Human colon carcinoma (HCT-116), human hepatocellular carcinoma (HEPG-2), 
adenocarcinomic human alveolar basal epithelial cell (A-549), and human breast 
adenocarcinoma (MCF-7) cell lines were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). The cells were grown on RPMI-1640 medium 
supplemented with 10% inactivated fetal calf serum and 50 µg/mL gentamycin. The cells  
were maintained at 37ºC in a humidified atmosphere with 5% CO2 and were subcultured 
two to three times a week. Potential cytotoxicity of the compounds was evaluated on tumor 
cells using the method of Gangadevi and Muthumary.130 The cells were grown as 
monolayers in growth RPMI-1640. The monolayers of 104 cells adhered at the bottom of 
the wells in a 96-well microliter plate incubated for 24 h at 37ºC in a humidified incubator 
with 5% CO2. The monolayers were then washed with sterile phosphate buffered saline 
(0.01 M pH 7.2) and simultaneously the cells were treated with 100 µL from different 
dilutions of tested sample in fresh maintenance medium and incubated at 37ºC. A control 
of untreated cells was made in the absence of tested sample. Positive controls containing 
doxorubicin were also tested as a reference drug for comparison. Six wells were used for 
each concentration of the test sample. Every 24-hour observation under the inverted 
microscope was made.  
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The number of the surviving cells was determined by staining the cells with crystal violet 
followed by cell lysing using 33% glacial acetic acid and the absorbance read at 590 nm 
using a microplate reader (SunRise, TECAN, Inc, USA) through mixing. 121,131 The 
absorbance values from untreated cells were considered as 100% proliferation. The number 
of viable cells was determined using microplate reader as previously mentioned and the 
percentage of viability was calculated as [1-(ODt/ODc)]x100% where ODt is the mean 
optical density of wells treated with the tested sample and ODc is the mean optical density 
of untreated cells. The relation between surviving cells and drug concentration was plotted 
to get the survival curve of each tumor cell line after treatment with the specified 
compound. The 50 % inhibitory concentration (IC50), the concentration required to cause 
toxic effects in 50% of intact cells, was estimated from graphic plots. 
 
3.5.3 Molecular modeling  
The newly synthesized compounds were docked into the crystal structure of E. coli 
topoisomerase II DNA gyrase B (PDB code 1KZN). The MOE software124 was used for 
all docking calculations. The MOE tools package was employed to generate the docking 
input files and to analyze the docking results. All non-polar hydrogens, clorobiocin, and 
crystal water molecules were removed prior to the calculations and the protonation of the 
enzyme was carried out and was energy minimized. In each case, 100 docked structures 
were generated using genetic algorithm searches. The 3D structures of new synthesized 
compounds were drawn in MOE and the protonation of ligands were carried out.  
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The energy of compounds was minimized up to 0.05 gradient using GBVI/WSA dG force 
field. These data were saved in database as input file MOE. Heavy atom comparison root 
means square deviations (RMSD values) were calculated and initial ligand binding modes 
were plotted. Protein-ligand interaction plots were generated using MOE 2012.10. 
Quantum mechanical calculations and surface molecular orbitals were generated by 
simulation module in MOE software. 
 
3.5.4 Synthesis 
3.5.4.1 General procedure for the synthesis of synthesis of 8-amino-10-phenyl-5-hydroxy-
2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydro-2H,10H-pyrano[2,3-f] chromene-9-carbonitrile 
derivatives 3.2(a-g).  
Aryl aldehyde (2.3 mmol) was added to a solution containing compound 3.1 (2.3 mmol) in 
5 mL of ethanol and malononitrile or ethyl cyanoacetate (2.3 mmol) with few drops of 
piperidine. The reaction mixture was stirred under reflux. After completion of the reaction 
(monitored by TLC), the mixture was kept at room temperature and the formed solid 
product was collected by filtration and washed with ethanol and hexane to yield 3.2(a-g). 
3.5.4.2 8-amino-10-(2-chlorophenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydr o 
-2H,10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2a). 
White solid (0.75g, 89.51 %), m.p. 262°C; IR (KBr) cm-1: 3489 (OH), 3360 (NH2), 2178 
(CN), 1634 (C=O); 1H NMR (DMSO, 300 MHz) δ 12.3 (s, 1H, C5-OH), 9.63 (s, 1H, C4`- 
OH), 7.39 (d, J = 7.5 Hz, 1H, H3``), 7.33 (d, J = 8.5 Hz, 2H, diastereomeric H2` & H6`),   
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7.32 (d, J = 8.5 Hz, 2H, diastereomeric H2` & H6`), 7.29-7.18 (m, 2H, H4`` & H5``), 7.15-
7.04 (m, 3H, overlapping H6`` & NH2), 6.80 (d, J = 8.5 Hz, 2H, H3` & H5`), 6.23 (s, 1H, 
H6), 5.55 (dd, J = 12.8, 2.8 Hz, 1H, diastereomeric H2), 5.53 (dd, J = 12.8, 2.8 Hz, 1H, 
diastereomeric H2), 5.08 (s, 1H, H10), 3.40 (dd, J = 17.1, 13.0 Hz, 1H, diastereomeric 
trans H3ax), 3.41 (dd, J = 17.1, 13.0 Hz, 1H, diastereomeric trans H3ax), 2.73 (dd, J = 
17.1, 2.7 Hz, 1H, diastereomeric cis H3eq),  2.70 (dd, J = 17.1, 2.7 Hz, 1H, diastereomeric 
cis H3eq); 13C NMR (DMSO, 75 MHz) δ 198.9 (C=O), 162.1 (C-5), 160.5 (C-13), 160.2 
(C-8), 158.8 (C-4), 156.6 (C-12), 142.6 (diastereomeric C-1``), 142.5 (diastereomeric C-
1``), 132.9 (C-2``), 132.8 (C-1`), 131.3 (diastereomeric C-4``), 131.2 (diastereomeric C-
4``), 130.4 (C-3``), 129.4 (C-2` & C-6`), 129.2 (C-5``), 128.4 (C-6``), 120.3 (CN), 116.1 
(C-3` & C-5`), 105.9 (C-14), 103.8 (C-11), 95.7 (diastereomeric C-6), 95.6 (diastereomeric 
C-6),  79.8 (diastereomeric C-2), 79.7 (diastereomeric C-2), 56.7 (diastereomeric C-9), 
56.6 (diastereomeric C-9), 43.0 (diastereomeric C-3), 42.7 (diastereomeric C-3), 34.0 (C-
10); Anal. Calcd for C25H17N2O5Cl: C, 65.15; H, 3.72; N, 6.08. Found: C, 65.34; H, 3.63; 
N, 6.02 
 
 3.5.4.3 8-amino-10-(2-fluorophenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydro 
-2H,10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2b). 
Yellow solid (0.52g, 71.51 % ), m.p. 290°C; IR (KBr) cm-1: 3497 (OH), 3403, 3192 (NH2), 
2198 (CN), 1647 (C=O); 1H NMR (DMSO, 300 MHz) δ 12.4 (s, 1H, C5-OH), 9.63 (s, 1H,  
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C4`-OH), 7.32 (d, J = 8.5 Hz, 1H, diastereomeric H2` & H6`), 7.31 (d, J = 8.5 Hz, 2H, 
diastereomeric H2` & H6`), 7.29-7.20 (m, 1H, H4``), 7.20-7.11 (m, 3H, H3``, H5`` & 
H6``), 7.09 (s, NH2), 6.80 (d, J = 8.5 Hz, 2H, H3`, H5`), 6.22 (s, 1H, H6), 5.55 (dd, J = 
12.2, 2.7 Hz, 1H, diastereomeric H2), 5.52 (dd, J = 12.6, 2.5 Hz, 1H, diastereomeric H2), 
4.82 (s, 1H, H10), 3.51-3.37 (m, 1H,  diastereomeric trans H3ax), 2.73 (dd, J = 17.1, 2.7 
Hz, 1H, diastereomeric cis H3eq), 2.70 (dd, J = 17.1, 2.7 Hz, 1H, diastereomeric cis H3eq); 
13C NMR (DMSO, 75 MHz) δ 198.0 (C=O), 162.6 (C-2``), 162.2 (C-5), 159.5 (C-13), 
159.3 (C-8), 157.9 (C-4`), 155.7 (C-12), 129.9 (C-1``), 128.5 (C2` & C-6`), 128.3 (C-1`), 
128.2 (C-4``), 124.5 (C-5``), 132.5 (C-6``), 119.7 (CN), 115.5 (diastereomeric C-3``), 
115.2 (C-3`), 115.1 (diastereomeric C-3``), 107.9 (diastereomeric C-14), 104.7 
(diastereomeric C-14), 102.8 (diastereomeric C-11), 100.1 (diastereomeric C-11), 94.8 
(diastereomeric C-6), 94.8 (diastereomeric C-6),  79.0 (diastereomeric C-2), 78.8 
(diastereomeric C-2), 56.0 (diastereomeric C-9), 55.7 (diastereomeric C-9), 42.2 
(diastereomeric C-3), 41.8 (diastereomeric C-3), 30.3 (diastereomeric C-10), 30.3 
(diastereomeric C-10); Anal. Calcd for C25H17N2O5F: C, 67.57; H, 3.86; N, 6.30. Found: 
C, 67.24; H, 3.98; N, 6.09  
3.5.4.4 8-amino-10-(3-bromophenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydro 
-2H,10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2c).  
White solid (0.72g, 77.42 %), m.p. 182°C; IR (KBr) cm-1: 3634(OH), 3424 (NH2), 2207 
(CN), 1653 (C=O); 1H NMR (DMSO, 300 MHz) δ 12.4 (s, 1H, C5-OH), 9.63 (s, 1H, C4`- 
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OH), 7.45-7.37 (m, 2H, H2` & H6`), 7.36-7.23 (m, 3H, H2``, H4`` & H5``), 7.21-7.10 (m, 
3H, H6`` & NH2), 6.80 (d, J = 8.5 Hz, 2H, H3` & H5`), 6.24 (s, 1H, H6), 5.56 (dd, J = 12.5, 
2.8 Hz, 1H, diastereomeric H2), 5.53 (dd, J = 13.1, 2.8 Hz, 1H, diastereomeric H2), 4.62 
(s, 1H, diastereomeric H10), 4.61 (s, 1H, diastereomeric H10), 3.42 (dd, J = 17.2, 13.5 Hz, 
1H, diastereomeric trans H3ax), 3.41 (dd, J = 17.6, 13.3 Hz, 1H, diastereomeric trans 
H3ax), 2.75 (dd, J = 17.4, 3.0 Hz, 1H, diastereomeric cis H3eq), 2.71 (dd, J = 17.1, 2.7 Hz, 
1H, diastereomeric cis H3eq); 13C NMR (DMSO, 75 MHz) δ 198.9 (C=O), 162.9 (C-5), 
160.4 (C-13), 160.3 (C-8), 158.8 (C-4’), 156.2 (C-12), 148.5 (C-1’’), 131.7 (C-2’’), 130.6 
(C-5’’),  129.4 (C-2’ & C-6`), 129.2 (C-1’), 128.5 (C-4’’), 127.2 (C-6’’), 122.5 (C-3’’), 
120.7 (CN), 116.1 (C-3` & C-5`), 105.7 (C-14), 104.3 (C-11), 96.0 (C6-H),  79.8 (C-2), 
57.7 (C-9), 43.0 (diastereomeric C-3), 42.9 (diastereomeric C-3), 36.2 (C-10);Anal. Calcd 
for C25H17N2O5Br: C, 59.42; H, 3.39; N, 5.54. Found: C, 59.74; H, 3.28; N, 5.31. 
 
3.5.4.5 8-amino-10-(4-tert-butylphenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihyd 
-ro-2H,10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2d). 
Yellowish white solid (0.74g, 84.36 %), m.p. 264°C; IR (KBr) cm-1: 3488 (OH), 3381 
(NH2), 2961- 2869 (CH), 2185 (CN), 1643 (C=O); Diastereomeric ratio: 1:1; 
1H NMR 
(DMSO, 300 MHz) δ 11.9 (s, 1H, C5-OH), 9.62 (s, 1H, C4`-OH), 7.30 (d, J = 8.3 Hz, 2H, 
H3``), 7.03 (br s, 2H, NH2), 6.94 (d, J = 8.2 Hz, 2H, H2``), 6.91 (d, J = 8.0 Hz, 2H, H2` & 
H6`), 6.74 (d, J = 8.1 Hz, 2H, H3` & H5`), 6.21 (s, 1H, H6), 5.07 (dd, J = 12.8, 2.5 Hz,   
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1H, H2), 4.46 (s, 1H, H10), 3.34 (dd, J = 17.1, 13.2  Hz, 1H, trans H3ax), 2.75 (dd, J = 
17.1, 2.7 Hz, 1H, cis H3eq); 1.33 (s, 9H, 3CH3); 
13C NMR (DMSO, 75 MHz) δ 198.7 
(C=O), 161.9 (C-5), 160.2 (C-13), 160.0 (C-8), 158.7 (C-4`), 156.3 (C-12), 149.7 (C-4``), 
142.9 (C-1``), 129.4 (C2` & C-6`), 127.7 (C-1`), 127.4 (C-2``), 126.0 (C-3``), 120.9 (CN), 
115.9 (C-3` & C-5`), 106.2 (C-14), 104.4 (C-11), 96.8 (C-6),  79.9 (C-2), 58.0 (C-9), 41.7 
(C-3), 36.2 (C-10), 35.0 (t-Bu quaternary carbon), 32.0 (CH3); Anal. Calcd for C29H26N2O5: 
C, 72.18; H, 5.43; N, 5.81. Found: C, 71.99; H, 5.20; N, 5.73. 
 
3.5.4.6 8-amino-10-(thiophene)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydro-2H- 
10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2e).  
White solid (0.68g, 88.31 %), m.p. 293°C; IR (KBr) cm-1: 3501 (OH), 3402, 3205 (NH2), 
2206 (CN), 1653 (C=O); 1H NMR (DMSO, 300 MHz) δ 12.5 (s, 1H, C5-OH), 9.63 (s, 1H, 
C4`-OH), 7.46-7.37 (m, 1H, H4``), 7.32 (d, J = 8.3 Hz, 2H, H2` & H6`), 7.20-7.14 (m, 1H, 
H2``), 7.11 (br s, 2H, NH2), 6.92-6.85 (m, 1H, H5``), 6.81 (d, J = 8.3 Hz, 2H, H3` & H5`),  
6.21 (s, 1H, H6), 5.59-5.43 (m, 1H, H2), 4.73 (s, 1H, diastereomeric H10), 4.71 (s, 1H, 
diastereomeric H10), 3.40 (dd, J = 17.3, 13.2 Hz, 1H, trans H3ax), 2.83-2.68 (m, 1H, cis 
H3eq);  13C NMR (DMSO, 75 MHz) δ 198.9 (C=O), 161.9 (C-8), 160.7 (C-13), 160.2 (C-
5), 158.8 (C-4`), 156.3 (C-12), 146.2 (C-1``), 129.4 (C-2` & C-6`), 129.1 (C-1`), 127.5 
(diastereomeric C-5``), 127.4 (diastereomeric C-5``), 127.3 (C-4``), 121.8 (diastereomeric   
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C-2``), 121.7 (diastereomeric C-2``), 121.0 (CN), 116.1 (C-3` & C-5`), 106.7 
(diastereomeric C-14),  106.6 (diastereomeric C-14), 105.3 (diastereomeric C-11), 105.2 
(diastereomeric C-11),  96.0 (diastereomeric C-6), 95.9 (diastereomeric C-6),   79.8 
(diastereomeric C-2), 79.7 (diastereomeric C-2), 57.6 (diastereomeric C-9), 57.5 
(diastereomeric C-9), 43.1 (diastereomeric C-3), 42.8 (diastereomeric C-3), 31.5 (C-10); 
Anal. Calcd for C23H16N2O5S: C, 63.88; H, 3.73; N, 6.48. Found: C, 63.64; H, 3.60; N, 
6.16.  
 
3.5.4.7 8-amino-10-(4-fluorophenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dihydro-
2H,10H-pyrano[2,3-f] chromene-9-carbonitrile (3.2f). 
Yellow solid (0.54g, 68.35 %), m.p. 276°C; IR (KBr) cm-1: 3494 (OH), 3400, 3197 (NH2), 
2193 (CN), 1649 (C=O); 1H NMR (DMSO, 300 MHz) δ 12.4 (s, 1H, C5-OH), 9.63 (s, 1H, 
C4`-OH), 7.32 (d, J = 8.5 Hz, 1H, diastereomeric H2` & H6`), 7.31 (d, J = 8.5 Hz, 2H, 
diastereomeric H2` & H6`), 7.23-7.11 (m, 4H, H2``, H6``, H5`` & H3``), 7.10 (s, NH2), 
6.80 (d, J = 8.5 Hz, 2H, H3` & H5`), 6.23 (s, 1H, H6), 5.54 (dd, J = 12.8, 3.0 Hz, 1H, 
diastereomeric H2), 5.53 (dd, J = 13.1, 3.0 Hz, 1H, diastereomeric H2), 4.61 (s, 1H, 
diastereomeric H10), 4.59 (s, 1H, diastereomeric H10),  3.41 (dd, J = 17.4, 13.2 Hz, 1H, 
diastereomeric trans H3ax), 2.74 (dd, J = 17.1, 2.9 Hz, 1H, diastereomeric cis H3eq), 2.71 
(dd, J = 17.3, 2.9 Hz, 1H, diastereomeric cis H3eq); 13C NMR (75 MHz, DMSO-d6) δ 
198.82 (C=O), 163.37 (C-4``), 161.93 (C-5), 159.92 (C-13), 159.36 (C-8), 157.56 (C-4`),  
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154.95 (C-12), 129.91 (C-1``), 131.39.81 (C-2` & C-6`), 130.07 (C-1`), ), 129.72 ( C-2`` & 
6``), 128.47 (C-3`` & C-5``), 120.74 (CN), 115.99 (diastereomeric C-3` & C-5`),116.85 
(diastereomeric C-3` & C-5`) 105.64 (C-14), 104.97 (C-11), 95.88 (diastereomeric C-6), 
95.76 (diastereomeric C-6), 79.78 (diastereomeric C-2), 79.67 (diastereomeric C-2), 53.58 
(C-9), 42.75 (C-3), 36.09 (C-10Anal. Calcd for C25H17N2O5F: C, 67.57; H, 3.86; N, 6.30. 
Found: C, 67.27; H, 3.74; N, 6.12 
 
3.5.4.8 Ethyl-8-amino-10-(3-nitrophenyl)-5-hydroxy-2-(4-hydroxy-phenyl)-4-oxo-3,4-dih- 
ydro-2H,10H-pyrano[2,3-f] chromene-9-carboxlate (3.2g). 
White solid (0.71g, 74.58 %), m.p. 230°C; IR (KBr) cm-1: 3477 (OH), 3411, 3294 (NH2), 
2914- 2880 (CH), 1686 (C=O); 1528, 1349 (NO); 1H NMR (DMSO, 300 MHz) δ 11.9 (s, 
1H, C5-OH), 9.70 (s, 1H, diastereomeric C4`-OH), 9.62 (s, 1H, diastereomeric C4`-OH), 
8.08-7.98 (m, 1H, H4``), 7.88 (s, 1H, diastereomeric H2``), 7.79 (br s, 2H, NH2), 7.62-7.35 
(m, 2H, H5`` & H6``), 7.11 (d, J = 8.7 Hz, 2H, diastereomeric H2` & H6`), 7.06 (d, J = 
8.7 Hz, 2H, diastereomeric H2` & H6`), 6.79 (d, J = 8.4 Hz, 2H, diastereomeric H3 & 
H5`), 6.72 (d, J = 8.6 Hz, 2H, diastereomeric H3` & H5`), 6.27 (s, 1H, diastereomeric H6), 
6.26 (s, 1H, diastereomeric H6), 5.64 (dd, J = 12.5, 2.9 Hz, 1H, diastereomeric H2), 5.07 
(dd, J = 13.6, 2.5 Hz, 1H, diastereomeric H2), 4.90 (s, 1H, diastereomeric H10), 4.83 (s, 
1H, diastereomeric H10), 4.03-3.81 (m, 2H, OCH2CH3) 3.45 (dd, J = 17.2, 13.4 Hz, 1H, 
diastereomeric trans H3ax), 3.11 (dd, J = 17.4, 12.9 Hz, 1H, diastereomeric trans H3ax),  
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2.72 (dd, J = 17.6, 3.1 Hz, 1H, diastereomeric cis H3eq), 2.66 (dd, J = 17.2, 2.7 Hz, 1H, 
diastereomeric cis H3eq); 0.98 (t, 3H, OCH2CH3); 
13C NMR (DMSO, 75 MHz) δ 198.7 
(diastereomeric C=O), 198.3 (diastereomeric C=O), 168.7 (Ester C=O), 162.1 
(diastereomeric C-5), 162.0 (diastereomeric C-5),160.8 (diastereomeric C-13), 160.7 
(diastereomeric C-13), 160.0 (diastereomeric C-8), 159.9 (diastereomeric C-8), 158.9 
(diastereomeric C-4`), 158.5 (diastereomeric C-4`), 156.1 (C-12), 149.6 (diastereomeric C-
3``), 149.6 (diastereomeric C-3``), 148.0 (C-1``), 135.2 (diastereomeric C-6``), 135.0 
(diastereomeric C-6``), 130.5 (diastereomeric C-5``), 130.4 (diastereomeric C-5``), 129.5 
(diastereomeric C-2` & C-6`), 128.5 (diastereomeric C-2` & C-6`), 128.4 (C-1`), 123.4 
(diastereomeric C-4``), 123.3 (diastereomeric C-4``), 122.0 (diastereomeric C-2``), 121.9 
(diastereomeric C-2``), 116.0 (diastereomeric C-3` & C-5`), 115.9 (diastereomeric C-3`& 
C-5`), 106.6 (diastereomeric C-14), 106.7 (diastereomeric C-14), 104.3 (C-11), 96.7 
(diastereomeric C-6), 96.6 (diastereomeric C-6), 80.2 (diastereomeric C-2), 80.0 
(diastereomeric C-2), 76.8 (diastereomeric C-9), 76.6 (diastereomeric C-9), 59.8 
(OCH2CH3), 43.4 (diastereomeric C-3), 43.0 (diastereomeric C-3), 35.3 (diastereomeric 
C-10), 35.3 (diastereomeric C-10), 15.0 (OCH2CH3); Anal. Calcd for C27H22N2O9: C, 
62.55; H, 4.28; N, 5.40. Found: C, 62.19; H, 3.99; N, 5.32. 
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Chapter Four: Synthesis, Antimicrobial, Cytotoxicity and Docking Studies of a New 
Family of Chromene Azo Dyes.  
 
4.1 Synopsis 
A variety of novel derivatives of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-4H-
benzo[h]chromene-3-carbonitrile 4.2(a-j) have been prepared via three component 
reaction of 1-naphthalenol-4-[(4-ethoxyphenyl) azo] 4.1 with benzaldehyde derivatives 
and malononitrile. The structures were confirmed on the basis of their spectral data and 
elemental analysis. Their antimicrobial activity was investigated and tested against four 
human pathogen Gram-positive and Gram-negative bacteria: Streptococcus pneumoniae, 
Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, and four fungi including 
Aspergillus fumigatus, Syncephalastrum racemosum, Geotricum candidum, and Candida 
albicans, using agar well diffusion method and minimum inhibitory concentrations were 
reported. Some newly prepared compounds exhibited antimicrobial activities against gram-
negative and fungi species compared to reference drugs. Compounds 4.2a, 4.2g, and 4.2h 
were found to be more effective against Syncephalastrum racemosm (RCMB 05922) by IZ 
range 20.1 to 21.4 mm and MIC 1.95 to 3.9 µg/ml compared to reference drugs, while in 
the case of the Gram-negative bacteria, the compounds 4.2b and 4.2h showed the highest 
inhibitory activity against E. coli by IZ range 20.4 to 21.2 mm and MIC = 3.9 µg/ml 
compared to reference drugs. The bathochromic shift of compound 4.2a was shown in 
solution when acidified.  
 
 
103 
 
Moreover, the cytotoxic activity was also evaluated against three different human cell lines 
including human colon carcinoma (HCT-116), human hepatocellular carcinoma (HepG-2), 
human breast adenocarcinoma (MCF-7), and adenocarcinoma human alveolar basal 
epithelial cell (A-549) cell lines. Some of tested compounds have good IC50 ranging from 
4.35 to 5.54 µg/mL against HCT-116 and MCF-7 cell line. The molecular modeling results 
showed binding interaction of synthesized compounds 3.2b, 3.2h in the active site of 
enzyme. 
 
4.2 Introduction  
4H-Chromenes are one class of the most biologically active heterocyclic compounds. The 
pharmacological and biochemical properties of simple 4H-chromenes depend upon pattern 
of substitution. In recent years,4H-chromene and its derivatives have attracted intense 
interest due to their diverse biological properties.4 The 4H-chromenes have long been 
recognized to possess antimicrobial and anticarcinogenic activates. These properties of 4H-
chromenes are interesting to warrant the synthesis of   new compounds featuring different 
heterocyclic rings fused to the chromene moiety in order to obtain more active compounds. 
On the other hand, azo dyes are characterized with presence of azo moiety (-N=N-) in their 
structure. They have found broad applications in analytical chemistry, pharmaceutical, 
cosmetic, food and dyeing. Additionally, azo dyes have various biological activities such 
as antibacterial, antifungal and anti-HIV properties.85 Biological activity of azo compounds 
result from specific reduction of azo bound.  
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In this reaction the azo bond is cleaved to release aromatic amine from the azo dye.156 This 
process can decrease or increase any toxic effect of the dyes. 157,158 The present study is 
focused on the possibility of synthesizing novel 4H-chromene compounds fused to azo dye 
moieties and studying in vitro antimicrobial activity and cytotoxic effects for these new 
derivatives. 
 
4.3 Results and Dissection 
4.3.1 Synthesis and Characterization 
In our attempts to synthesize chromene derivatives, 2-amino-6-(4-ethoxyphenylazo)-4(-
phenyl)-4H-benzo[h]chromene-3-carbonitrile derivatives were obtained in good yield by 
three component condensation of 1-naphthalenol-4-[(4-ethoxyphenyl) azo] (Fat Brown B) 
4.1 with benzaldehyde derivatives and malononitrile or ethyl cyanoacetate under reflux 
using piperidine in ethanol, (Table 4.1). Knoevenagel condensation followed by Michael 
addition adducts is the common method for this synthesis113, as shown in the following 
Scheme 4.1 
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i)  CH2 (CN)2 or 
C4H5O2N
ii)  ArCHO
iii)  EtOH / Piperidine
4.1 4.2(a-j)  
Scheme 4.1: Synthesis of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-4H-benzo[h]chrom 
-ene derivatives 4.2(a-j) 
 
Compound No. R1 R2 R3 R4 Yield% 
4.2a CN F H H 
62.05 
4.2b CN Cl H H 
74.92 
4.2c CN Br H H 
58.29 
4.2d CN H Br H 
60.57 
4.2e CN H Cl H 
67.43 
4.2f CN H H F 
55.58 
4.2g CN H NO2 H 
65.99 
4.2h COOCH3 Br H H 
58.43 
4.2i COOCH3 Cl H H 
50.78 
4.2j COOCH3 H Br H 
78.26 
Table 4.1: The yields of new synthesized derivatives 4.2(a-j)  
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The first step of this multicomponent process begins with Knoevenagel condensation and 
then followed by Michael addition adducts85, as shown in the following Scheme 4.2. 
C C
CN
CN
Ar
N OH
NO
H
N
NO
OH
C
CNAr
H
N
N
NO
O
C
CNAr
H
NH
N
NO
O
CNAr
NH2
 
Scheme 4.2: General synthesis and mechanistic pathway of chromene molecules 4.2(a-j) 
 
The structures of new chromene compounds 4.2(a-j) were confirmed with the aid of 
spectroscopic data. FT-IR spectroscopy showed characteristic absorption bands between 
2187 and 2210 cm-1 for the CN groups while the NH2 stretches were in the range of 3336-
3470 cm-1. The 1H NMR spectra of chromene compounds 4.2(a-j) were obtained in 
DMSO-d6. As anticipated, the methyl protons appeared as a triplet set at 1.34-1.37 ppm, 
while the H4 pyran showed signals at 5.07-5.49 ppm and the amine protons resonated at 
6.71-7.11 ppm. The singlet at 4.11-4.19 ppm corresponds to the methylene group.  
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The rest of the aromatic protons resonate further downfield in the range of 6.62-8.97 ppm. 
Figure 4.1 shows one example of the proton NMR for compound 4.2c.  
Figure 4.1: 1H NMR of Compound 4.2c 
 
The13C NMR spectra of the synthesized compounds showed that the carbon atoms attached 
to the methyl protons resonate at 15.40-14.48 ppm, while the methylene carbons resonate 
at 64.58-64.14 ppm. The signal at 41.71-31.52 ppm corresponds to the C-4 of the pyran 
ring, while the quaternary carbon C-2 that is attached to the amine group appeared in the 
range of 58.49-55.67 ppm.  
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The CN carbon resonated further downfield at 118.92-117.69 ppm and the aromatic CH 
carbons showed signals between 144.06 and 111.75 ppm. Figure 4.2 shows 13C NMR 
spectrum of 4.2c as example.  
 
 
Figure 4.2: 13C NMR of Compound 4.2c  
 
The absorption spectra of the new synthesized compounds 4.2(a-j) in DMF showed two 
bands around 393 and 591 nm with almost similar width as shown in Figure 4.3.  
109 
 
 
Figure 4.3: UV-vis absorption spectra of compounds 4.2(a-j) (10µM) in DMF  
 
Addition of an acidic solution to these compounds caused a bathochromic shift in the 
absorption maxima. For example, after addition of acid to 4.2a two absorption bands 
observed at 524 and 408 nm as shown in Figure 4.4. 
 
Figure 4.4: wavelength of 4.2a in the presence of increasing [H+] (HCl) in a DMF  
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In the same time the colour of DMF solution of compound 4.2a was changed when exposed 
to H+, due to the formation of the azonium form of the azo group allowing for the visual 
identification of aqueous acid. Compound 4.2a for example, changed from yellow/green 
in DMF to orange as the concentration of H+ increased and as concentration increased 
further the colour changed from orange to dark pink (Figure 4.5) 
 
 
 
 
 
 
 
 
Figure 4.5: Colour change of 4.2a in the presence of increasing [H+] (HCl) in a DMF.  
 
4.3.2 Biological Screening  
4.3.2.1 Antimicrobial screening  
The synthesized compounds 4.2(a-j) in this chapter were screened for their antibacterial, 
and antifungal, activities via agar diffusion well method.117 The inhibition zones and 
minimum inhibitory concentrations (MIC) were determined by serial dilution method.118  
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The activity of the synthesized compounds was tested against two Gram-positive bacteria 
including Streptococcus pneumoniae (RCMB 010010), Bacillus subtilis (RCMB 010067), 
two Gram-negative bacteria including Pseudomonas aeruginosa (RCMB 010043), 
Escherichia coli (RCMB 010052), and four fungi including Aspergillus fumigatus (RCMB 
02568), Syncephalastrum racemosum (RCMB 05922), Geotricum candidum (RCMB 
05097), and Candida albicans (RCMB 05036). Ampicillin, gentamicin and amphotericin 
B were used as control drugs. 119,120 The observed inhibition zone (IZ) and minimum 
inhibitory concentrations (MIC) of the compounds and the reference drugs are given in 
Table 4.2, 4.3 and presented in Figure 4.6, 4.7. Among the synthesized compounds 4.2a, 
4.2g, 4.2h and 4.2i were found to be more effective against Syncephalastrum racemosm 
(RCMB 05922) by IZ range 20.1 to 21.4 mm and MIC 1.95 to 3.9 µg/mL compared to 
reference drugs. The values of inhibition zone (IZ) and minimum inhibitory concentrations 
(MIC) of the target compounds against A.F and G.C revealed that most of the synthesized 
compounds were found to be comparable active to the reference drugs. In the case of the 
Gram-negative bacteria, the highest inhibitory activity against E. coli was showed by IZ 
range 20.4 to 21.2 mm and MIC = 3.9 µg/ml for compounds 4.2b and 4.2h compared to 
reference drugs. The synthesized compounds were moderately or slightly active against the 
S.P and B.S, while all the compounds did not show any antimicrobial activity against P.A 
and C.A. Generally, the investigation of antimicrobial activity of the novel derivatives 
showed greater than the reference drugs against E. coli and S.R and mild or slightly activity 
towards gram-positive bacteria.  
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Table 4.2: Antimicrobial activity of synthetic compounds (IZ, diameter (mm)) (1 g/mL). 
Compounds 
Inhibition Zone Diameter (mm) 
Gram-
positive 
Gram-negative Fungi 
S. P B. S P. A E.C A. F S.R G.C C.A 
4.2a 20.3 20.9 NA 15.4 18.6 20.1 20.6 NA 
4.2b 18.4 12.2 NA 20.4 20.9 19.2 22.8 NA 
4.2c 17.4 20.2 NA 17.3 16.2 15.3 17.1 NA 
4.2d 19.6 20.0 NA 15.9 18.2 17.3 18.9 NA 
4.2e 20.3 23.4 NA 19.4 18.6 15.3 19.2 NA 
4.2f 20.3 21.4 NA 16.9 17.6 18.4 20.6 NA 
4.2g 18.9 20.3 NA 18.9 16.3 20.3 21.4 NA 
4.2h 21.4 23.4 NA 21.2 23.3 21.4 25.2 NA 
4.2i 19.6 21.4 NA 19.3 18.2 20.3 20.8 NA 
4.2j 16.0 18.3 NA 13.0 10.6 18.7 23.4 NA 
Ampicillin 23.8 32.4 - - - - - - 
Gentamicin - - 17.3 19.9 - - - - 
Amphotericin 
B 
- - - - 23.7 19.7 28.7 25.4 
Mean zone of inhibition in mm from at least three experiments; (triplicate, mean ± SE, with 
standard errors range 0.01- 0.8). (NA) means no activity. S.P (Streptococcus pneumoniae), 
B.S (Bacillus subtilis), P.A (Pseudomonas aeruginosa), E.C (Escherichia coli), S.T 
(Salmonella typhimurium), A.F Aspergillus fumigatus (RCMB 02568), G.C Geotricum 
candidum (RCMB 05097), S.R Syncephalastrum racemosum (RCMB 05922), and C.A 
Candida albicans (RCMB 05036). 
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Figure 4.6: Evaluation of Inhibition zone values (IZ) of synthesized derivatives.  
 
Compounds 
Minimal inhibitory concentration (MIC, µg/ml) 
Gram-positive Gram-negative Fungi 
S.P B.S P.A E.C A.F S.R G.C C.A 
4.2b 7.81 1.95 NA 3.9 1.95 3.9 0.98 NA 
4.2g 3.9 3.9 NA 1.95 3.25 3.9 1.95 NA 
4.2h 1.95 0.98 NA 3.9 0.98 1.95 0.49 NA 
Ampicillin 0.98 0.24 - - - - - - 
Gentamicin - - 
15.6
3 
3.9 - - - - 
Amphotericin 
B 
- - - - 0.98 3.9 0.49 0.49 
 
Table 4.3: Antimicrobial activity of synthetic compounds (MIC, µg/mL). 
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Minimum inhibitory concentration (MIC, mg/mL), results are mean values from at least 
three experiments (triplicate, mean ± SE, with standard errors range 0.1-0.7). (NA) means 
no activity. 
 
Figure 4.7: Evaluation of minimum inhibitory concentration values (MIC). of compounds. 
 
4.3.2.2 Cytotoxic screening 
The in vitro cytotoxic activity was performed by MTT assay121,122 against three human 
carcinoma cell lines: Human colon carcinoma (HCT-116) human breast adenocarcinoma 
(MCF-7) and human hepatocellular carcinoma (HepG-2) cell lines. Doxorubicin was used 
as a positive control, since it has high cytotoxic activity. The inhibitory effects of 
synthesized compounds 4.2(a-j) on the growth of the three cell lines are shown in Table 
4.4 and Figure 4.8. All compounds showed comparable or slight cytotoxicity to the 
reference drug. The new synthesized derivatives 4.2e, 4.2h and 4.2j exhibited good IC50 
ranging from 4.35 to 5.54 µg/mL against of HCT-116 and MCF-7 cell lines, while all 
compounds showed less activity in case of HepG-2 cell line. 
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Table 4.4: Cytotoxicity of chromene derivatives against three different cancer cell lines. 
Compounds 
 
IC
50
 (µg/mL) 
HCT-116 MCF-7 HepG-2 
4.2a 24.1 21.9 11.6 
4.2b 19.2 16.2 11.3 
4.2c 12.2 21.1 7.28 
4.2d 15.3 9.16 7.64 
4.2e 5.54 19.7 9.99 
4.2f 24.6 22.5 14.3 
4.2g 9.01 7.14 12.0 
4.2h 10.9 5.5 9.19 
4.2i 23.0 11.5 8.76 
4.2j 4.35 4.72 11.6 
Doxorubicin 0.88 1.02 1.19 
Cytotoxicity activity results from at least three experiments (triplicate, mean ±SE, with 
standard errors range 0.02- 0.7). Cytotoxic effects of compounds on colon, breast, liver, 
and epithelial cell lines following exposure to different concentrations of compounds, and 
cell viability was assessed 
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Figure 4.8: Evaluation of cytotoxic activity of target compounds compared to reference 
drug. 
 
4.3.3 Computational studies  
4.3.3.1 Docking studies 
The molecular docking calculations of the synthesized derivatives 4.2b and 4.2h were 
performed to gain insight into the plausible mechanism of antibacterial activity of the target 
compounds. Molecular modeling studies using the DNA gyrase B subunit were performed, 
as it has been reported as a good target for studying inhibitory activity against these 
bacteria.123. E. coli topoisomerase II DNA gyrase B (responsible for the super-coiling 
activity of DNA in bacteria) (PDB code: 1KZN; resolution 2.30 Å) was used by docking 
module implemented in MOE software. 124,125 The least energy binding mode of the 
compounds has been studied. Figure 4.9 presents the best docking poses for all 
investigated chromene derivatives inside topoisomerase II DNA gyrase B binding pocket.  
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The bound fat brown B displayed interaction including hydrogen bonding interaction with 
Asp 73 (2.45 Å)  
 
 
 
4.2b 
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4.2h 
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Fat brown B 
Figure 4.9: 2D and 3D binding interaction of target compounds, 4.2h, 4.2b and fat brown 
B inside the enzyme. 
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The results of the docking experiments were summarized in Table 4.5. The 2D and 3D 
binding map of the target compounds 4.2b and 4.2h in the pocket is explained through 
three different fragments around the chromene scaffold, 8-NH2, 9-CN and -Br belong to 
4.2h. These fragments form stable hydrogen bonding interactions with a panel of 
corresponding pocket residues: Asp 73, Thr 165, Asn 46, Asp 49 and Lie 78 with different 
distance between 2.00 and 3.23 Å. 
 
Compound No. 4.2b 4.2h Fat Brown B 
Amino acid 
(Distance Å) 
Asp 73 
-NH2  
(2.3, 2.4) 
- --OH (2.4) 
Thr 165 -CN (3.2) - - 
Asn 46 - --NH2 (2.0) - 
Asp 49 - --Br (3.2) - 
Lie 78 - -phenyl  
Interaction type H-bonding 
H-bonding  
(aromatic) 
H-bonding 
∆G (kcal/mol) 
-13.61 -12.23 -11.24 
 
Table 4.5: Description of the docking data of the selected target compounds 
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The data reported in the table are extracted from MOE program showing the corresponding 
amino acids residues in enzyme pocket, corresponding fragments of ligands, interaction 
distances, types of interaction, and their binding energy to some selected drugs compared 
to reference drug. 
 
4.4 Conclusions 
We have synthesized a series of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-4H-benzo [h] 
chromene-3-carbonitrile derivatives 4.2(a-j) based on 1-naphthalenol-4- [(4-ethoxy 
phenyl) azo] 4.1 by reaction of benzaldehyde derivatives and malononitrile or ethyl 
cyanoacetate in an ethanol and few drops of piperidine (Knoevenagel condensation) 
followed by the electrophilic substitution step of 1-naphthalenol-4-[(4-ethoxyphenyl) azo] 
4.1(Michael addition adduct). All synthesized compounds were characterized by IR and 
NMR. The antimicrobial activity of synthesized derivatives showed greater than the 
reference drugs against fungal species and Gram-negative bacteria and slight activity 
towards Gram-positive bacteria. The novel compounds were found to have comparable or 
slightly greater cytotoxicity effects compared to the reference compounds. Compounds 
4.2e, 4.2h and 4.2j have good IC50 ranging from 4.35 to 5.54 µg/mL against HCT-116 and 
MCF-7 cell lines. Moreover, all the target derivatives showed less activity in case of HepG-
2 cell line. The docking study results showed binding interaction of synthesized compounds 
3.2b, 3.2h in the active site of enzyme. 
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4.5 Experimental Section   
 
4.5.1 Materials and Instrumentation   
Chemicals and solvents were purchased from Sigma-Aldrich (Canada) and Alfa Aesar, and 
were used as received. Compound 4.1 was purchased from Sigma-Aldrich (Canada). 
Melting points were determined in open capillaries using an electrothermal apparatus and 
are uncorrected. The progress of the reactions was monitored using thin layer 
chromatography (TLC) on Merck silica gel 60 F254 plates. Infrared (IR) spectra were 
recorded using Bruker Alpha FT-IR Spectrometer as pressed KBr pellets. 1H-NMR and 
13C-NMR spectra were recorded on a 300 MHz and at 75 MHz, respectively, on a Bruker 
Avance Spectrometer in DMSO-d6 with tetramethylsilane as internal standard. The high 
vacuum for overnight and heat gun were used to removed residual water from the 
compounds. Elemental analyses for C, H and N were performed using an Exeter Analytical, 
Inc. CE-440 Elemental Analyzer. UV-vis absorption measurements were performed using 
a HP8543 UV-vis spectrophotometer. 
 
4.5.2 Biological Studies  
4.5.2.1 Antimicrobial Screening 
The microorganism inoculums were uniformly spread using sterile cotton swabs on a 
sterile Petri dish malt extract agar (for fungi) and nutrient agar (for bacteria). One hundred 
cubic millimeters of each sample was added to each well (10-mm-diameter holes were cut  
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in the agar gel, 20 mm apart from one another). The systems were incubated for 24–48 hr. 
at 37oC (for bacteria) and at 28oC (for fungi). After incubation, microorganism growth was 
observed. Inhibition zones of the bacterial and fungal growth were measured in 
millimeters. Tests were performed in triplicate. 113,114 
 
4.5.2.2 Cytotoxic Screening 
Human colon carcinoma (HCT-116), human hepatocellular carcinoma (HepG-2), 
adenocarcinomic and human breast adenocarcinoma (MCF-7) cell lines were obtained 
from the American Type Culture Collection (ATCC, Rockville, MD). The cells were 
grown on RPMI-1640 medium supplemented with 10% inactivated fetal calf serum and 50 
µg/mL gentamycin. The cells were maintained at 37ºC in a humidified atmosphere with 
5% CO2 and were subcultured two to three times a week. Potential cytotoxicity of the 
compounds was evaluated on tumor cells using the method of Gangadevi and 
Muthumary.130 The cells were grown as monolayers in growth RPMI-1640. The 
monolayers of 104 cells adhered at the bottom of the wells in a 96-well microliter plate 
incubated for 24 h at 37ºC in a humidified incubator with 5% CO2. The monolayers were 
then washed with sterile phosphate buffered saline (0.01 M pH 7.2) and simultaneously the 
cells were treated with 100 µL from different dilutions of tested sample in fresh 
maintenance medium and incubated at 37 ºC. A control of untreated cells was made in the 
absence of tested sample. Positive controls containing doxorubicin were also tested as a 
reference drug for comparison.  
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Six wells were used for each concentration of the test sample. Every 24-hour observation 
under the inverted microscope was made. The number of the surviving cells was 
determined by staining the cells with crystal violet followed by cell lysing using 33% 
glacial acetic acid and the absorbance read at 590 nm using a microplate reader (SunRise, 
TECAN, Inc, USA) through mixing. 121,131 The absorbance values from untreated cells 
were considered as 100% proliferation. The number of viable cells was determined using 
microplate reader as previously mentioned and the percentage of viability was calculated 
as [1-(ODt/ODc)]x100% where ODt is the mean optical density of wells treated with the 
tested sample and ODc is the mean optical density of untreated cells. The relation between 
surviving cells and drug concentration was plotted to get the survival curve of each tumor 
cell line after treatment with the specified compound. The 50 % inhibitory concentration 
(IC50), the concentration required to cause toxic effects in 50% of intact cells, was 
estimated from graphic plots. 
 
4.5.3 Molecular modeling  
The newly synthesized compounds were docked into the crystal structure of E. coli 
topoisomerase II DNA gyrase B (PDB code 1KZN). The MOE software124 was used for 
all docking calculations. The MOE tools package was employed to generate the docking 
input files and to analyze the docking results. All non-polar hydrogens, clorobiocin, and 
crystal water molecules were removed prior to the calculations and the protonation of the 
enzyme was carried out and was energy minimized.  
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In each case, 100 docked structures were generated using genetic algorithm searches. The 
3D structures of new synthesized compounds were drawn in MOE and the protonation of 
ligands were carried out. The energy of compounds was minimized up to 0.05 gradient 
using GBVI/WSA dG force field. These data were saved in database as input file MOE. 
Heavy atom comparison root means square deviations (RMSD values) were calculated and 
initial ligand binding modes were plotted. Protein-ligand interaction plots were generated 
using MOE 2012.10. 
 
4.5.4 Synthesis 
4.5.4.1 General procedure for the synthesis of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-
4H-benzo[h]chromenederivatives  
A mixture of compound 4.1 (2.3 mmol), malononitrile or ethyl cyanoacetate (2.3 mmol), 
and aryl aldehyde (2.3 mmol) in ethanol (5 mL) and few drops of pipredine was added. 
The reaction mixture was stirred under reflux. After completion of the reaction (monitored 
by TLC), the mixture was cooled and filtered, washed with ethanol and hexane to afford 
the 4.2(a-j). 
4.5.4.2 2-amino-6-(4-ethoxyphenylazo)-4-(2-fluoro-phenyl)-4H-benzo [h] chromene-3-
carbonitrile (4.2a) 
Brown solid (0.48g, 62.05 %), m.p.  205°C; IR (KBr) cm-1: 3469, 3280 (NH2), 2925, 2891 
(CH), 2201 (CN), 1571 (N=N); 1H NMR (300 MHz, DMSO) δ 8.87 – 8.83 (m, 1H, Ar-H), 
8.39 – 8.34 (m, 1H, Ar-H), 7.94 (d, J = 8.9 Hz, 2H, Ar-H), 7.81 – 7.77 (m, 2H, Ar-H), 7.41  
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(s, 1H, Ar-H), 7.37 – 7.28 (m, 4H, Ar-H, NH2), 7.22 – 7.14 (m, 2H, Ar-H), 7.10 (d, J = 9.0 
Hz, 2H, Ar-H), 5.27 (s, 1H, H4), 4.14 (q, J = 6.7 Hz, 2H, CH2), 1.36 (t, J = 6.8 Hz, 3H, 
CH3); 
13C NMR (75 MHz, DMSO) δ 162.30 (C-2), 160.96, 147.53, 146.07, 143.96, 132.72 
(Ar-C), 132.55, 131.35 (Ar-CH), 131.15 (Ar-C), 130.35, 128.81 (Ar-CH), 128.32 (Ar-C), 
125.76, 124.11, 121.98, 120.85 (Ar-CH), 117.80 (CN), 116.95 (Ar-C), 116.67, 115.90, 
112.18 (Ar-CH), 64.57 (CH2), 55.67 (C-3), 31.52 (CH-4), 15.39 (CH3); Anal. Calcd for 
C28H21N4O2F: C, 72.40; H, 4.56; N, 12.06. Found: C, 72.05; H, 4.50; N, 11.87.  
 
4.5.4.3 2-amino-6-(4-ethoxyphenylazo)-4-(2-chloro-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2b) 
Greenish-brown solid (0.60g, 74.92%), m.p.  219°C; IR (KBr) cm-1: 3466, 3326 (NH2), 
2995, 2973, 2932 (CH), 2197 (CN), 1567 (N=N); 1H NMR (300 MHz, DMSO) δ 8.81-8.79 
(m, 1H, Ar-H), 8.37-8.34 (m, 1H, Ar-H), 7.90 (d, J = 8.8 Hz, 2H, Ar-H), 7.78 – 7.75 (m, 
2H, Ar-H), 7.45 (d, J = 7.1 Hz, 1H, H), 7.40-7.21 (m, 6H, Ar-H,NH2), 7.07 (d, J = 8.8 Hz, 
2H, Ar-H), 5.46 (s, 1H, H4), 4.11 (q, J =  6.7 Hz, 2H, CH2), 1.35 (t, J = 6.8 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 162.32 (C-2), 160.86, 147.49, 146.03, 143.92, 142.72 (Ar-
C), 133.01, 132.22, 131.38 (Ar-CH), 130.93 (Ar-C), 129.98, 128.87, 128.35 (Ar-CH), 
125.78 (Ar-C), 124.07, 123.97, 122.03, 120.71 (Ar-CH), 117.69 (CN), 115.91 (Ar-CH), 
111.87 (Ar-C), 64.57 (CH2), 55.78 (C-3),  31.53 (CH-4) 15.39 (CH3); Anal. Calcd for 
C28H21N4O2Cl: C, 69.92; H, 4.40; N, 11.65. Found: C, 70.25; H, 4.20; N, 11.76.  
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4.5.4.4 2-amino-6-(4-ethoxyphenylazo)-4-(2-bromo-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2c) 
Brown solid (0.51g, 58.29 %), m.p. 208°C; IR (KBr) cm-1: 3468, 3326 (NH2), 2995, 2973, 
2932 (CH), 2198 (CN), 1569 (N=N); 1H NMR (300 MHz, DMSO) δ 8.86 – 8.80 (m, 1H, 
Ar-H), 8.39 – 8.34 (m, 1H, Ar-H),, 7.92 (d, J = 9.0 Hz, 2H, Ar-H), 7.80 – 7.76 (m, 2H, Ar-
H), 7.64 (d, J = 7.5 Hz, 1H, Ar-H), 7.40 – 7.27 (m, 5H, Ar-H, NH2), 7.25 – 7.19 (m, 1H, 
Ar-H), 7.09 (d, J = 9.0 Hz, 2H, Ar-H), 5.49 (s, 1H, H4), 4.13 (q, J = 6.9 Hz, 2H, CH2), 1.36 
(t, J = 6.9 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 162.32 (C-2), 160.78, 147.46, 
145.89, 143.91 (Ar-C), 134.10, 132.45, 131.39, 130.24 (Ar-CH), 129.54 (Ar-C), 128.86, 
128.34, 125.78 (Ar-CH), 124.11(Ar-C), 123.96 (Ar-CH), 123.32 (Ar-C), 122.06, 120.65 
(Ar-CH), 117.80 (CN), 115.89 (Ar-CH), 111.75 (Ar-C), 64.56 (CH2), 56.01 (C-3), 31.53 
(CH-4), 15.38 (CH3); Anal. Calcd for C28H21N4O2Br: C, 64.01; H, 4.03; N, 10.66. Found: 
C, 64.32; H, 3.78; N, 10.78.  
 
4.5.4.5 2-amino-6-(4-ethoxyphenylazo)-4-(3-bromo-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2d) 
Brown solid (0.53g, 60.57 %), m.p.  217°C; IR (KBr) cm-1: 3466, 3335 (NH2), 2975, 2935, 
2883 (CH), 2193 (CN), 1566 (N=N); 1H NMR (300 MHz, DMSO) δ 8.89 – 8.80 (m, 1H, 
Ar-H), 8.37 – 8.36 (m, 1H, Ar-H),, 7.95 (d, J = 9.0 Hz, 2H, Ar-H), 7.81-7.77 (m, 2H, Ar-
H), 7.50 (s, 1H, Ar-H), 7.46-7.42 (m, 2H, Ar-H), 7.34 – 7.29 (m, 4H, Ar-H, NH2),  
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7.12 (d, J = 9.0 Hz, 2H, Ar-H), 5.09 (s, 1H, H4), 4.15 (q, J = 6.9 Hz, 2H, CH2), 1.37 (t, J 
= 6.9 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ162.33 (C-2), 160.68, 149.15, 147.55, 
145.82 (Ar-C), 144.06, 132.04, 131.33 (Ar-CH), 131.20 (Ar-C), 130.94, 128.88, 128.36 
(Ar-CH), 127.83 (Ar-C), 125.78, 124.22 (Ar-CH), 122.89 (Ar-C), 122.05, 120.89 (Ar-CH), 
118.38 (CN), 115.93 (Ar-CH), 112.48 (Ar-C), 64.58 (CH2), 56.89 (C-3), 31.53 (CH-4), 
15.40 (CH3) Anal. Calcd for C28H21N4O2Br: C, 64.01; H, 4.03; N, 10.66. Found: C, 64.27; 
H, 3.77; N, 10.80.  
 
4.5.4.6 2-amino-6-(4-ethoxyphenylazo)-4-(3-chloro-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2e) 
Dark brown solid (0.54 g, 67.43 %), m.p. 212°C; IR (KBr) cm-1: 3470, 3336 (NH2), 2979, 
2927, 2875 (CH), 2194 (CN), 1566 (N=N); 1H NMR (300 MHz, Acetone) δ 8.97-8.90 (m, 
1H-Ar-H), 8.44-8.38 (m, 1H-Ar-H), 7.98 (d, J = 8.9 Hz, 2H, Ar-H), 7.80 – 7.73 (m, 2H, 
Ar-H), 7.55 (s, 1H, Ar-H), 7.43-7.27 (m, 4H, Ar-H, NH2), 7.15 (d, J = 11.7 Hz, 1H, Ar-H), 
7.12 (d, J = 9.0 Hz, 2H, Ar-H), 6.62 (s, 1H, Ar-H), 5.11 (s, 1H, H4), 4.19 (q, J = 7.0 Hz, 
2H, CH2), 1.43 (t, J = 7.0 Hz, 3H, CH3); 
13C NMR (75 MHz, Acetone) δ 162.40 (C-2), 
148.39,  147.68, 144.49, 134.54, 131.60 (Ar-C), 130.95, 128.32 (Ar-CH), 128.10 (Ar-C), 
127.70, 127.05, 125.34 (Ar-CH), 125.16 (Ar-C), 124.34, 123.77, 122.49, 121.60, 119.23 
(Ar-CH), 117.95 (CN), 115.28 (C-Ar-CH), 112.22 (Ar-C), 64.14 (CH2), 58.49 (C-3), 41.71 
(CH-4), 14.48 (CH3); Anal. Calcd for C28H21N4O2Cl: C, 69.92; H, 4.40; N, 11.65. Found: 
C, 70.17; H, 4.21; N, 11.70. 
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4.5.4.7 2-amino-6-(4-ethoxyphenylazo)-4-(4-fluoro-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2f)  
Greenish-brown solid (0.43g, 55.58 % ), m.p. 214°C; IR (KBr) cm-1: 3466, 3278 (NH2), 
2979, 2935, 2869 (CH), 2187 (CN), 1567 (N=N); 1H NMR (300 MHz, DMSO) δ 8.86 – 
8.81 (m, 1H, Ar-H), 8.38 – 8.35 (m, 1H, Ar-H), 7.95 (d, J = 8.9 Hz, 2H, Ar-H), 7.81 – 7.76 
(m, 2H, Ar-H), 7.41 (s, 1H, Ar-H), 7.35 – 7.27 (m, 4H, Ar-H, NH2), 7.19 – 7.09 (m, 4H, 
Ar-H), 5.07 (s, 1H, H4), 4.15 (d, J = 7.0 Hz, 2H, CH2), 1.37 (t, J = 6.9 Hz, 3H, CH3); 
13C 
NMR (75 MHz, DMSO) δ 162.31(C-2), 160.51, 147.54, 145.74, 143.99, 142.69, 131.26 
(Ar-C), 130.59, 130.48 (Ar-CH), 128.81 (Ar-C), 128.32, 125.76, 125.24 (Ar-CH), 124.21 
(Ar-C), 123.98, 122.02 (Ar-CH), 120.99 (Ar-C), 118.92 (CN), 116.61, 116.32, 115.92, 
112.60 (Ar-CH), 64.57 (CH2), 57.34 (C-3), 31.54 (CH-4), 15.40 (CH3); Anal. Calcd for 
C28H21N4O2F: C, 72.40; H, 4.56; N, 12.06. Found: C, 72.16; H, 4.32; N, 11.80  
 
4.5.4.8 2-amino-6-(4-ethoxyphenylazo)-4-(3-nitro-phenyl)- 4H-benzo [h] chromene-3-
carbonitrile (4.2g) 
Brown solid (0.54g, 65.99 %), m.p.  216°C; IR (KBr) cm-1: 3418, 3331 (NH2), 2980, 2967, 
2923 (CH), 2210 (CN), 1571 (N=N), 1473, 1352 (NO2); 
1H NMR (300 MHz, DMSO) δ 
8.85 – 8.81 (m, 1H, Ar-H), 8.41 – 8.37 (m, 1H, Ar-H), 8.18 (s, 1H, Ar-H), 8.12 (d, J = 8.0 
Hz, 1H, Ar-H), 7.92 (d, J = 8.9 Hz, 2H, Ar-H), 7.82 – 7.76 (m, 3H, Ar-H), 7.64 (d, J = 7.8 
Hz, 1H, Ar-H), 7.45-7.41 (m, 3H, Ar-H, NH2), 7.09 (d, J = 8.9 Hz, 2H, Ar-H), 5.32 (s, 1H, 
H4), 4.12 (q, J = 6.8 Hz, 2H, CH2), 1.35 (t, J = 6.9 Hz, 3H, CH3); 
13C NMR (75 MHz,   
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DMSO) δ 162.33 (C-2), 160.83, 148.91, 148.58, 147.50, 145.91, 144.16 (Ar-C), 135.47, 
131.47 (Ar-CH), 131.39 (Ar-C), 128.96, 128.40, 125.75 (Ar-CH), 124.23 (Ar-C), 124.02, 
123.14, 122.98 (Ar-CH), 122.07 (Ar-C), 120.80 (Ar-CH), 117.99 (CN), 115.89, 112.43 
(Ar-CH), 64.56 (CH2), 56.56 (C-3), 31.52 (CH-4), 15.38 (CH3); Anal. Calcd for 
C28H21N5O4: C, 68.42; H, 4.31; N, 14.25. Found: C, 68.73; H, 4.20; N, 14.02.  
 
4.5.4.9 Ethyl-2-amino-6-(4-ethoxyphenylazo)-4-(2-bromo-phenyl)-4H-benzo[h]chromene 
-3-carboxylate (4.2h)  
Dark brown solid (0.56g, 58.43 % ), m.p. 145.2°C; IR (KBr) cm-1:  3451, 3296 (NH2), 
2981, 2939, 2885 (CH), 1674 (CO), 1516 (N=N); 1H NMR (300 MHz, DMSO) δ 8.80 (dd, 
J = 5.9, 2.5 Hz, 1H, Ar-H), 8.42 (dd, J = 6.2, 3.4 Hz, 1H, Ar-H), 7.91 (m, 4H, Ar-H, NH2), 
7.79 – 7.71 (m, 2H, Ar-H), 7.67 (s, 1H, Ar-H), 7.56 (d, J = 7.7 Hz, 1H, Ar-H), 7.27 – 7.19 
(m, 2H, Ar-H), 7.11-7.05 (m, 3H, Ar-H), 5.64 (s, 1H, H4), 4.12 (q, J = 6.8 Hz, 2H, CH2), 
3.51 (s, 3H, OCH3), 1.36 (t, J = 6.6 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 169.22 
(C=O), 168.92, 162.25 (Ar-C), 161.22 (C-2), 147.61, 147.47, 145.45 (Ar-C), 143.94, 
133.50, 131.21, 129.24 (Ar-CH), 129.12 (Ar-C), 128.58, 128.15, 125.72 (Ar-CH), 124.20 
(Ar-C), 123.16 (Ar-CH), 122.96 (Ar-C), 122.07 (Ar-CH), 120.94 (Ar-C), 115.89, 111.92 
(Ar-CH), 76.29 (C-3), 64.55 (CH2), 51.36 (OCH3), 28.16 (CH-4), 15.38 (CH3); Anal. Calcd 
for C29H24N3O4Br: C, 62.94; H, 4.58; N, 7.34. Found: C, 63.25; H, 4.32; N, 7.62. 
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4.5.4.10 Ethyl-2-amino-6-(4-ethoxyphenylazo)-4-(2-chloro-phenyl)-4H-benzo[h]chrome-
ne -3-carboxylate (4.2i)  
Light brown solid (0.45g, 50.78 % ), m.p. 139.9-140°C; IR (KBr) cm-1: 3454, 3316 (NH2), 
2977, 2934 (CH), 1675 (CO), 1535 (N=N); 1H NMR (300 MHz, DMSO) δ 8.79-8.76 (m, 
1H, Ar-H), 8.41 – 8.37 (m, 1H, Ar-H), 7.93 – 7.86 (m, 4H, Ar-H, NH2), 7.75-7.67 (m, 2H, 
Ar-H), 7.56 (s, 1H, Ar-H), 7.37 (dd, J = 6.8, 1.10 Hz, 1H, Ar-H), 7.26 (ddd, J = 7.7, 3.7, 
1.10 Hz, 1H,  Ar-H), 7.20 (ddd, J = 6.6, 3.7, 1.7 Hz, 1H, Ar-H), 7.13 (dd, J = 7.6, 1.7 Hz, 
1H, Ar-H), 7.05 (d, J = 9.0 Hz, 2H, Ar-H), 5.60 (s, 1H, H4), 4.08 (q, J = 6.9 Hz, 2H, CH2), 
3.52 (s, 3H, OCH3), 1.33 (t, J = 6.9 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 207.36 
(C=O), 169.18, 168.88, 162.24 (Ar-C), 161.36 (C-2), 147.49, 145.54, 143.93 (Ar-C), 
132.27, 131.24, 131.19 (Ar-CH), 130.33 (Ar-C), 128.88, 128.58, 128.16, 125.81 (Ar-CH), 
124.14 (Ar-C), 123.89, 122.05 (Ar-CH), 120.71 (Ar-C), 115.89, 112.05 (Ar-CH), 75.97 
(C-3), 64.55 (CH2), 51.38 (OCH3 ), 32.97 (CH-4), 15.38 (CH3); Anal. Calcd for 
C29H24N3O4Cl: C, 68.24; H, 4.96; N, 7.96. Found: C, 68.57; H, 4.73; N, 8.19.  
 
4.5.4.11 Ethyl-2-amino-6-(4-ethoxyphenylazo)-4-(3-bromo-phenyl)-4H-benzo[h]chrome-
ne-3-carboxylate (4.2j)  
Orange solid (0.75g, 78.26 %), m.p. 158.9°C; IR (KBr) cm-1: 3489, 3346 (NH2), 2976, 
2949, 2871 (CH), 1675 (CO), 1487 (N=N); 1H NMR (300 MHz, DMSO) δ 8.82 (dd, J = 
5.5, 3.1 Hz, 1H, Ar-H), 8.43 (dd, J = 6.4, 3.5 Hz, 1H, Ar-H), 7.95 (d, J = 8.9 Hz, 2H, Ar-
H), 7.89 (s, 2H, NH2), 7.80 – 7.71 (m, 2H, Ar-H), 7.60 (s, 1H, Ar-H), 7.43 (s, 1H, Ar-H),  
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7.33-7.26 (m, 2H, Ar-H), 7.22-7.18 (m, 1H, Ar-H), 7.11 (d, J = 9.0 Hz, 2H, Ar-H), 5.16 (s, 
1H, H4), 4.13 (q, J = 6.9 Hz, 2H, CH2), 3.57 (s, 3H, OCH3), 1.36 (t, J = 6.9 Hz, 3H, CH3); 
13C NMR (75 MHz, DMSO) δ 169.05 (C=O), 162.25 (Ar-C), 161.31 (C-2), 151.13, 147.57, 
145.96, 144.14 (Ar-C), 131.64 (Ar-CH), 131.12 (Ar-C), 130.73, 130.08, 128.60, 128.18, 
127.35, 125.72 (Ar-CH), 124.19 (Ar-C), 123.97 (Ar-CH), 122.51 (Ar-C), 122.05 (Ar-CH), 
121.46 (Ar-C), 115.88, 112.89 (Ar-CH), 79.93 (C-3), 78.32 (CH2), 57.67 (OCH3), 39.95 
(CH-4), 18.45 (CH3); Anal. Calcd for C29H24N3O4Br: C, 62.94; H, 4.58; N, 7.34. Found: 
C, 63.20; H, 4.36; N, 7.54. 
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Chapter Five: Conclusions 
     Chromenes are one of many families of biologically active compounds which have been 
used in the treatment of different diseases for many years. A large number of chromene 
derivatives have many varying activities. In this thesis I designed and synthesized several 
new chromene derivatives based on three different moieties of biologically active 
compounds and in vitro evaluated their antimicrobial and cytotoxic activities to the 
development of new antibiotic and anticancer drugs.  
     The biological importance of coumarin scaffold and the study of some reported 4-
hyroxy coumarin based natural products have encouraged me to design novel antimicrobial 
agents with high potency and target selectivity. A synthetic route to these novel 8-amino-
10-phenyl-5-hydroxy-2-oxo-4-propyl-2H, 10H-pyrano [2,3-f] chromene-9-carbonitrile 
derivatives 2.2(a-j) has been successfully achieved. The key step represents a condensation 
of benzaldehyde derivatives and malononitrile in an ethanol with few drops of piperidine 
(Knoevenagal condensation) followed by the electrophilic substitution step of 5,7-
dihydroxy-4-propyl-chromen-2-one (Michael addition adduct) and producing the desired 
products. Fluorescence of the new compounds showed emission peaks at around 450 nm 
with good quantum yields.  The new synthesized compounds were screened for testing 
their antimicrobial activity against seven bacteria, four fungi, and one mycobacterium. The 
activity data show that these novel compounds have potent antibacterial and antifungal 
activities compared to reference drugs.  
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The inhibition zones cover a good range of activity, with corresponding minimum 
inhibitory concentrations. Analysis of the mode of action through docking experiments was 
reported. In addition, a cytotoxic screening evaluation step was employed against four 
human cancer cell lines and the resulting inhibition was comparable or greater than the 
reference drug.  
     In this study I prepared novel 8-amino-10-phenyl-5-hydroxy-2-(4-hydroxyphenyl)-4-
oxo-3,4-diydro-2H,10H-pyrano [2,3-f] chromene derivatives 3.2(a-g) and evaluation of 
their antimicrobial activity and cytotoxic effects. These target compounds were 
synthesized by condensation of benzaldehyde derivatives and malononitrile in an ethanolic 
piperidine (Knoevenagal condensation) followed by the electrophilic substitution step of 
4`5,7-trihydroxy-flavanone (Michael addition adduct). The structures of synthesized 
compounds were established from spectral data. The results of antibacterial assay revealed 
that the compounds 3.2a, 3.2b and 3.2(d-g) exhibited the highest inhibitory activity against 
P.A and E. coli by IZ range 18.3 to 24.6 mm and MIC 0.49 to 3.9 µg/mL compared to 
reference drugs. Compounds 3.2a, 3.2b and 3.2e were found to be more effective against 
S.T by IZ 23.4-26.4 mm. The antibacterial activity of the most compounds was found to 
be comparably active to reference drugs against gram-positive bacteria. Moreover, the 
cytotoxic activity was also evaluated against four different human carcinoma cell lines. 
Most of these compounds have good inhibitory activity against HCT-116 cell line (IC50= 
1.08-1.48 µg/ml). Finally, compound 3.2c showed no antimicrobial activity against any of 
the tested bacteria, fungi and TB.  
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The molecular modeling results showed binding interaction of synthesized compounds 
3.2a, 3.2b, 3.2d, 3.2e and kaempferol in the active site of GyrB. 
     Additionally, synthesis of new several of 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-
4H-benzo [h] chromene-3-carbonitrile derivatives 4.2(a-j) was reported in this thesis, 
which was based on 1-naphthalenol-4- [(4-ethoxy phenyl) azo] 4.1 by reacting of 
benzaldehyde derivatives and malononitrile or ethyl cyanoacetate in an ethanol and few 
drops of piperidine (Knoevenagal condensation) followed by the electrophilic substitution 
step of 1-naphthalenol-4-[(4-ethoxyphenyl) azo] 4.1(Michael addition adduct). All 
synthesized compounds were characterized by IR and NMR. The antimicrobial activity of 
synthesized derivatives showed greater than the reference drugs against fungal species and 
Gram-negative bacteria and slightly activity towards Gram-positive bacteria. The novel 
compounds were found to be comparable or slightly cytotoxicity effects. Compounds 4.2e, 
4.2h and 4.2j have good IC50 ranging from 4.35 to 5.54 µg/mL against of HCT-116 and 
MCF-7 cell lines. Moreover, all the target derivatives showed less activity in case of HepG-
2 cell line. The docking study results for new synthesized compounds 3.2b and 3.2 h was 
reported. Bothe of these two compounds have different interaction with different amino 
acid inside the gyrase B. 
     Finally, a protocol was developed combining chemistry and biology for design and 
synthesis of potent antimicrobial and cytotoxic effects of 8-amino-10-phenyl-5-hydroxy-
2-oxo-4-propyl-2H, 10H-pyrano[2,3-f] chromene-9-carbonitrile derivatives 2.2 (a-j), 8-
amino-10-phenyl-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-diydro-2H,10H-pyrano[2,3- 
 
 
136 
 
f] chrome-ne derivatives 3.2(a-g) and 2-amino-6-(4-ethoxyphenylazo)-4(-phenyl)-4H-
benzo [h] chromene-3-carbonitrile derivatives 4.2(a-j). A series of novel chromene 
derivatives based on three different moieties of biologically active compounds were 
synthesized and their antibacterial and anti-cancer activities were evaluated in vitro. The 
molecular modeling results showed binding interaction of some new synthesized 
compounds in the active site of Gyrase B. Future study could focus on chromenes 
combination with coumarin and flavanone moieties due to they have more biological activity than 
azo dyes.  
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Appendix 
A.1 NMR data for Chapter two 
 
 
 
 
 
 
 
 
 
Figure A.1: 1H NMR spectrum of 2.2a 
 
 
 
 
 
 
 
 
 
 
 
Figure A.2: DEPTQ135 13C NMR spectrum of 2.2a 
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Figure A.3: 1H NMR spectrum of 2.2b 
 
 
Figure A.4: DEPTQ135 13C NMR spectrum of 2.2b 
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Figure A.5: 1H NMR spectrum of 2.2c 
 
 
Figure A.6: 13C NMR spectrum of 2.2c 
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Figure A.7: 1H NMR spectrum of 2.2d  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8: DEPTQ135 13C NMR spectrum of 2.2d 
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Figure A.9: 1H NMR spectrum of 2.2e 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.10: 13C NMR spectrum of 2.2e 
 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
1
4
.5
7
1
9
.7
6
2
2
.9
5
3
1
.9
4
3
7
.1
3
3
8
.3
2
4
4
.9
1
5
7
.0
9
5
8
.2
9
1
0
0
.6
0
1
0
9
.5
8
1
1
1
.1
8
1
2
0
.7
6
1
2
2
.7
6
1
2
7
.3
5
1
3
0
.5
4
1
3
1
.9
4
1
4
8
.1
1
1
4
9
.3
1
1
5
6
.2
9
1
5
7
.6
9
1
6
0
.8
8
10 9 8 7 6 5 4 3 2 1 ppm
0
.
9
3
9
0
.
9
6
4
0
.
9
8
8
1
.
5
7
8
1
.
6
0
2
1
.
6
2
6
1
.
6
5
0
2
.
8
4
9
2
.
8
7
2
2
.
8
9
6
2
.
9
1
9
2
.
9
4
8
2
.
9
6
8
2
.
9
8
5
3
.
0
2
3
3
.
0
4
6
3
.
0
7
0
3
.
0
9
3
3
.
1
1
6
5
.
9
5
9
6
.
3
4
4
6
.
9
9
1
7
.
1
3
2
7
.
1
5
8
7
.
2
3
5
7
.
2
6
1
7
.
2
8
7
7
.
3
0
4
7
.
3
7
0
7
.
3
9
6
152 
 
 
 
 
 
 
 
 
 
 
 
Figure A.11: 1H NMR spectrum of 2.2f 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.12: 13C NMR spectrum of 2.2f 
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Figure A.13: 1H NMR spectrum of 2.2g 
 
 
 
 
 
 
 
 
 
 
 
Figure A.14: DEPTQ135 13C NMR spectrum of 2.2g 
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Figure A.15: 1H NMR spectrum of 2.2h  
 
 
Figure A.16: 13C NMR spectrum of 2.2h 
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Figure A.17: 1H NMR spectrum of 2.2i 
 
 
Figure A.18: 13C NMR spectrum of 2.2i 
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Figure A.19: 1H NMR spectrum of 2.2j 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.20: DEPTQ135 13C NMR spectrum of 2.2j 
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A.2 NMR data for Chapter Three   
 
Figure A.21: 1H NMR spectrum of 3.2a   
 
 
Figure A.22: DEPTQ135 13C NMR spectrum of 3.2a  
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Figure A.23: COSY NMR spectrum of 3.2a 
 
Figure A.24: HSQC NMR spectrum of 3.2a 
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Figure A.25: HMBC NMR spectrum of 3.2a 
 
 
Figure A.26: 1H NMR spectrum of 3.2b  
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Figure A.27: DEPTQ135 13C NMR spectrum of 3.2b 
 
 
Figure A.28: COSY NMR spectrum of 3.2b 
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Figure A.29: HSQC NMR spectrum of 3.2b 
 
 
Figure A.30: HMBC NMR spectrum of 3.2b 
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Figure A.31: 1H NMR spectrum of 3.2c 
 
 
Figure A.32: DEPTQ135 13C NMR spectrum of 3.2c 
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Figure A.33: COSY NMR spectrum of 3.2c 
 
 
Figure A.34: HSQC NMR spectrum of 3.2c 
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Figure A.35: HMBC NMR spectrum of 3.2c 
 
Figure A.36: 1H NMR spectrum of 3.2d 
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Figure A.37: DEPTQ135 13C NMR spectrum of 3.2d 
 
 
Figure A.38: COSY NMR spectrum of 3.2d 
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Figure A.39: HSQCNMR spectrum of 3.2d 
 
Figure A.40: HMBC NMR spectrum of 3.2d 
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Figure A.41: 1H NMR spectrum of 3.2e 
 
 
Figure A.42: DEPTQ135 13C NMR spectrum of 3.2e 
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Figure A.43: COSY NMR spectrum of 3.2e 
 
Figure A.44: HSQC NMR spectrum of 3.2e 
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Figure A.45: HMBC NMR spectrum of 3.2e 
 
 
Figure A.46: 1H NMR spectrum of 3.2f 
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Figure A.47: DEPTQ135 13C NMR spectrum of 3.2f 
 
 
Figure A.48: 1H NMR spectrum of 3.2g 
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Figure A.49: DEPTQ135 13C NMR spectrum of 3.2g 
 
 
Figure A.50: COSY NMR spectrum of 3.2g 
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Figure A.51: HSQC NMR spectrum of 3.2g 
 
Figure A.52: HMBC NMR spectrum of 3.2g 
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A.3 NMR data for Chapter Four  
 
 
Figure A.53: 1H NMR spectrum of 4.2a   
 
 
Figure A.54: 13C NMR spectrum of 4.2a 
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Figure A.55: 1H NMR spectrum of 4.2b  
 
 
  Figure A.56: 13C NMR spectrum of 4.2b 
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Figure A.57: 1H NMR spectrum of 4.2c 
 
 
Figure A.58: 13C NMR spectrum of 4.2c 
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Figure A.59: 1H NMR spectrum of 4.2d 
 
 
Figure A.60: 13C NMR spectrum of 4.2d 
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Figure A.61: 1H NMR spectrum of 4.2e 
 
 
Figure A.62: 13C NMR spectrum of 4.2e 
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Figure A.63: 1H NMR spectrum of 4.2f  
 
 
Figure A.64: 13C NMR spectrum of 4.2f 
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Figure A.65: 1H NMR spectrum of 4.2g  
 
 
Figure A.66: 13C NMR spectrum of 4.2g   
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Figure A.67: 1H NMR spectrum of 4.2h  
 
 
Figure A.68: 13C NMR spectrum of 4.2h   
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Figure A.69: 1H NMR spectrum of 4.2i  
 
 
Figure A.70: 13C NMR spectrum of 4.2i 
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Figure A.71: 1H NMR spectrum of 4.2j   
 
 
Figure A.72: 13C NMR spectrum of 4.2j 
 
 
